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Bacteria form biofilms by adhering to surfaces and secreting high 
molecular weight macromolecules. When in the biofilm mode of growth, bacteria 
possess increased resistance to the action of antimicrobials and the immune 
system. By gaining an increased understanding of the structure of the biofilm 
extrapolymeric substance (EPS) and investigating ways to break up the EPS 
matrix, more effective treatment of biofilm-related infections can be achieved. In 
this thesis, the isolation and characterization of the polysaccharide portion of the 
EPS of several bacterial species is reported. The identification of 14 possible 
biofilm-degrading enzymes is described. One of these enzymes, HexNW, is 
shown to be highly thermostable and effective as a biofilm treatment.   
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Background and Literature Review 
 
Overview 
While bacterial pathogenesis mechanisms, virulence factors, and 
antimicrobial resistance vary greatly between species, the ability and preference 
to grow as biofilms represents the vast majority of human bacterial infections. 
Biofilms are formed when planktonic bacteria (i.e., free, individual cells) adsorb 
onto a wound surface and form colonies (Hall-Stoodley et al. 2004; Stewart et al. 
2008; Stoodley, et al. 2002). Once the colonies become established, phenotypic 
changes cause them to secrete high molecular weight carbohydrates (i.e., 
polysaccharides) that serve as the structural backbone for the biofilm. Non-
cellular components and debris, including additional carbohydrates, proteins, 
lipids, and nucleic acids, become entangled in the polysaccharide backbone and 
constitute the “slime” layer of a biofilm which is technically known as the 
extrapolymeric substance, or EPS (Flemming and Wingender 2010).  The EPS is 
thought to protect the bacteria from antimicrobials, antibodies, and circulating 
immune cells. 
The natural resilience of biofilms along with the rise of antibiotic-resistant 
pathogens illustrates the urgent need for new and innovative ways to treat biofilm-
related infections.  Biofilms are responsible for complications such as secondary 
wound infections, chronic P. aeruginosa infection in the lungs of cystic fibrosis 
patients, and the colonization of medical implant devices.  As an example, 
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coagulase-negative staphylococci, which are typically viewed as less virulent than 
their coagulase-positive counterparts, including S. aureus, are responsible for 
about 250,000 cases of intravascular catheter infections per year with a cost of 
about $25,000 per case and hospital stays exceeding 7 days (Otto 2012). 
Research focused on ways of treating bacterial infections specific to 
biofilm-formers is lacking.  Methods include the use of metal chelators, phages, 
or modifications to surfaces with silver nanoparticles.  In addition, proteins that 
digest components of the EPS (EPS depolymerases) can be effective.  As the 
matrix that encapsulates bacterial cells is degraded, they revert to a planktonic 
lifestyle and are resensitized to the action of immune cells and antibiotics.  In 
order to understand how to degrade the EPS, it is important to know its 
composition.  In this thesis, the discovery of many EPS polysaccharide 
depolymerases is described that have good prospects as antibiofilm agents.  In 
addition, the analysis of the structural components of the polysaccharide portion 
of the EPS of many clinically relevant human pathogens is reported in an effort to 
aid in the identification of enzymes targeted to specific species. 
 
Biofilm structure 
Biofilms allow prokaryotes to live in varied and often harsh environments 
and reflects a level of adaptation that is not possible by multicellular eukaryotes 
(Hall-Stoodley et al. 2004).  Genetic regulation and selection for certain structures 
or matrix components combined with an increased resistance to environmental 
stressors allows for this increased level of adaptation.  The structures of mature 
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biofilms can be incredibly varied and depend on the environment in which the 
biofilm bacteria live.  For example, biofilms growing in fast-moving water often 
form filamentous “streamers” whereas biofilms growing in calm water tend to 
form mushroom- or mound-like structures.  In addition, there is a great deal of 
heterogeneity within individual biofilms and they often consist of multiple 
bacterial species.  The EPS is used to create numerous microdomains within the 
overall biofilm structure that vary both in terms of structure and of biochemical 
composition, as demonstrated by lectin staining (Lawrence et al. 2007; Flemming 
and Wingender 2010). 
The EPS matrix allows biofilms to be mechanically stable while also 
dynamic in their responses to shear stress and other mechanical forces.  The 
entanglement of matrix components and interactions between them such as 
hydrogen bonds, Van der Waals interactions, and electrostatic interactions confers 
stability, as illustrated in Figure 1-1.  Charged groups in the EPS are often 
capable of chelating multivalent ions (shown with Ca2+ in P. aeruginosa 
biofilms, Körstgens et al. 2001). Biofilms’ elasticity allows it to resist breakage 
(demonstrated in S. aureus, Lawrence et al. 2007).  In addition, biofilms are 
capable of phenotypic adaptation in response to changes in mechanical stresses 
(for example, increasing EPS production in response to stress, Stoodley et al. 
2003).  Increased fluid shear has been shown to result in the growth of denser and 





Figure 1-1: EPS stabilizing forces. The extracellular polymeric substances that make up a typical 
bacterial biofilm are visualized at several dimensions.  (A) Biofilm development begins with 
attachment, then microcolony formation and further development with increased cell division and 
EPS production.  (B) Components of the EPS visualized, including DNA, proteins, and 
polysaccharides.  (C) Various cohesive forces within the EPS are depicted.  Figure taken from 




 The EPS can account for over 90% of the biofilm’s dry mass (Wingender 
et al. 1999) and allows for a lifestyle that is vastly different from that of 
planktonic (free-living) cells.  Common components of the EPS include 
polysaccharides, proteins, DNA, and humic substances (compounds formed by 
the degradation of organic matter).  The EPS mediates adherence of the biofilm to 
surfaces and allows the cells within the biofilm to aggregate together.  It permits 
retention of water, nutrients, and digestive enzymes due to hydrogen bonding, 
charged interactions, and other intermolecular forces facilitated by the 
macromolecules present in the matrix.  The EPS also serves as a physical barrier 
between bacterial cells and the host immune system (in the case of pathogens).  It 
can shield bacterial cells from antimicrobial compounds, protozoan grazers, and 
ultraviolet radiation.  The presence of extracellular DNA in the EPS (which is due 
to both cell lysis and active export of DNA segments) also facilitates the 
exchange of genetic information between members of bacterial populations.  The 
EPS can even serve as a food source in and of itself during starvation conditions 
(Flemming and Wingender 2010). 
Exopolysaccharides (secreted polysaccharides) are a major constituent of 
the EPS matrix and are ubiquitous in environmental and disease-associated 
biofilms.  In many cases, they are essential for biofilm formation because of their 
role in surface attachment and maintaining the physical stability of the biofilm.  
They are typically long and high molecular weight (0.5 x 106 Da to 2 x 106 Da) 
(Flemming and Wingender 2010).  While some exopolysaccharides, such as 
cellulose, are homopolysaccharides, most are heterogenous and consist of a 
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mixture of charged and neutral sugar residues (Zogaj et al. 2001).  Many 
exopolysaccharides, such as alginate, are polyanionic (Ryder et al. 2007), whereas 
others, such as intercellular adhesin (partially deacetylated β-1,6-N-
acetylglucosamine, which is present in Staphylococcus aureus and 
Staphyloccocus epidermidis), are polycationic (Götz 2002).  In some cases, a 
single bacterial species utilizes multiple types of exopolysaccharides.  
Pseudomonas aeruginosa, for example, uses at least 3 different 
exopolysaccharides during biofilm development, including alginate, Pel, and Psl 
(Ryder et al. 2007). 
Proteins that exist in the EPS serve a variety of functions, including 
enzymes that degrade EPS components and other biopolymers that serve as a food 
source (Flemming and Wingender 2010).  They are also often implicated in the 
detachment of individual cells or larger sections of biofilm for the purpose of 
colonizing other areas.  They can serve as virulence factors in the case of 
pathogens.  The effect of extracellular enzymes is enhanced by the fact that the 
interactions between enzymes and other matrix components keep them from 
diffusing away from the biofilm.  These interactions also serve the purpose of 
enhancing the in situ thermostability and resistance to proteolysis of these 
enzymes.  Proteins such as lectins and lectin-like proteins can serve a structural 
role in biofilms by cross-linking exopolysaccharides and linking 
exopolysaccharides to bacterial cells themselves.  Amyloids are common matrix 
proteins that serve as adhesins and also cytotoxins (Otzen and Nielsen 2008).  
Structural proteins that serve other functions for bacterial cells, such as flagella, 
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fimbriae, and pili, can also play a role in the stabilization of the EPS matrix.  P. 
aeruginosa type IV pili, for example, bind DNA and are likely involved in the 
cross-linking of cells to extracellular DNA (Zogaj et al. 2001). 
Extracellular DNA (eDNA) is present in different amounts in different 
biofilms.  While S. aureus and S. epidermidis are closely related species, eDNA 
plays a much larger role in S. aureus than S. epidermidis (Izano et al. 2008).  
eDNA is also important in cell-cell adhesion in P. aeruginosa biofilms 
(Whitchurch et al. 2002).  While some eDNA is present in the EPS as a byproduct 
of “accidental” cell lysis, it is apparent that, in some cases, subpopulations of cells 
are specifically lysed for the sake of utilizing their DNA as a component of the 
EPS matrix.  This is the case for S. epidermidis, which mediates cell lysis through 
the AtlE autolysin (Molin and Tolker-Nielsen 2003).  In addition, the eDNA 
sequence of bacterial cells is not always identical to that of genomic DNA, 
suggesting that DNA may be exported from cells specifically for the purpose of 
building the EPS matrix (Böckelmann et al. 2006). 
While the polysaccharides, proteins, and DNA that are present in the EPS 
are highly hydrophilic, bacteria can also use hydrophobic molecules to allow for 
attachment to otherwise uncolonizable surfaces such as pyrite, oil droplets, 
Teflon, and waxy leaves.  These molecules include lipopolysaccharides (LPS), 
other lipids, surfactin, emulsan, and various biosurfactants (Flemming and 
Wingender 2010).  The EPS matrix allows biofilms to retain water during periods 
of dessication while at the same time acting like a molecular sieve, retaining ions 
and even toxic compounds such as heavy metals.  By allowing bacteria to 
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colonize hydrophobic surfaces such as oil slicks and also providing an effective 
way of retaining toxic metals, biofilms provide numerous environmental benefits 
in addition to allowing bacteria to colonize diverse environments. 
 
Biofilm formation	  
Biofilms develop in a regulated sequence (illustrated in Figure 1-2), 
beginning with loose association with a surface followed by strong adhesion as 
EPS is produced and facilitates increased binding (Stoodley et al. 2002).  
Irreversible attachment in S. epidermidis is caused by the production of 
polysaccharide intercellular adhesion (PIA), which holds adherent cells closely 
together (Gerke et. al 1998).  In P. putida, the transition from reversible to 
irreversible attachment is correlated with a switch from flagellar to twitching 
motility (Sauer et al. 2001).  Twitching motility is thought to contribute to 
microcolony formation (O’Toole and Kolter 1998).  Motility contributes to these 
initial steps of biofilm formation by allowing for attached cells to redistribute 
themselves on a surface, whereas cell division is the driving force of the lateral 
and vertical growth of the biofilm structures.  In addition, planktonic cells in the 
medium can be recruited to the developing biofilm.  Quorum sensing has been 
shown to play a role in bacterial biofilm formation, causing an upregulation of 
EPS producing genes as the number of adherent cells increases.  In P. aeruginosa, 
a strain lacking the autoinducer gene lasI produced biofilms that were only 20% 






Figure 1-2: Biofilm formation. The development of a biofilm as a five stage process: Stage 1: 
initial attachment of planktonic cells to the surface. Stage 2: production of EPS resulting in more 
firmly adhered “irreversible” attachment. Stage 3: early development of biofilm architecture.  
Stage 4: maturation of biofilm architecture. Stage 5: dispersion of single cells from the biofilm 





be involved in the conversion of biofilm cells to stationary phase and the 
expression of stress-response genes. 
As adherent cells divide, they manifest as microcolonies.   Confocal laser 
microscopy has shown biofilms as matrix-enclosed microcolonies with water 
channels between them to allow for efficient nutrient uptake and waste removal 
(Hall-Stoodley et al. 2004; Lawrence et al. 1991).  They then develop into mature 
biofilm structures with the increased production of EPS.  Biofilm structure varies 
based on the environment that the biofilm-forming cells are in.  Mature biofilms 
can have the appearance of mushroom-like mounds, flat mounds, or filaments if 
they are growing in an area of flowing water.  The nature of the EPS being 
produced also has a large impact on the nature of the mature biofilm architecture.   
If conditions permit, mature biofilms can disperse its cells with the goal of 
colonizing new niches.  Dispersal can occur through swarming/seeding dispersal, 
in which individual cells are released, dumping dispersal, in which clumps of cells 
are shed all at once, or surface dispersal, in which whole biofilm structures move 
across surfaces.  Dispersal is caused by enzymatic degradation of the EPS 
molecules that anchor cells to a surface, by external forces such as increased fluid 
shear, or the release of the EPS or surface-binding proteins that connect cells to 
the surface they are adhered to (Hall-Stoodley et al. 2004). 
 
Problems associated with biofilms 
  As already mentioned, biofilms serve to protect bacterial cells from 
environmental stresses such as UV radiation, metal toxicity, dehydration, 
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phagocytosis, and the action of antimicrobial agents.  The EPS matrix functions as 
a protective physical barrier and even if antimicrobials are able to penetrate, 
biofilm cells are usually in stationary phase and phenotypically well adapted to 
withstand stress (Hall-Stoodley et al. 2004).  As an example, β-lactam antibiotics 
(which act by inhibiting cell wall biosynthesis and are regularly used to treat 
infections caused by Gram-positive bacteria) are often either ineffective or require 
a higher killing dose because of the slow-growing nature of biofilm cells (Walters 
et al. 2003).  Antimicrobial degrading enzymes, such as β-lactamases, can also 
accumulate in biofilms and increase the likelihood of resisting antibiotic treatment 
even further (Dibdin et al. 1996). The EPS also decreases the rate of diffusion of 
antibiotics through the biofilm, decreasing the effective antibiotic concentration 
and increasing the likelihood of bacterial survival. Finally, in many biofilms, 
pockets of cells known as persisters exist that exhibit resistant phenotypes.   
The adaptations listed above create significant problems for humans being 
treated with a biofilm-forming bacterial species because while an initial treatment 
course of antibiotics may effectively kill planktonic bacteria and eliminate 
symptoms of infection, bacteria in a biofilm often resist such treatment and are 
then free to disperse and cause secondary infections.  Free-floating bacteria can 
also adhere to and colonize medical implant devices such as heart valves, 
catheters, and prosthetic joints.  It is even possible for the body’s defense 
mechanisms to actually encourage biofilm formation.  It has been shown that 
certain host inflammatory molecules facilitate bacterial adhesion to surfaces.  
Many biofilm-forming bacteria possess receptors for host cell proteins that 
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facilitate adhesion.  For example, several bacterial species, including S. aureus, 
possess adhesins for fibronectin, a common eukaryotic structural protein 
(Vaudaux et al. 1994). 
Bacterial endocarditis is an example of how bacterial biofilms can 
incorporate host components as a part of the biofilm extracellular matrix (Hall-
Stoodley et al. 2004).  When heart valves are damaged, platelets and fibrin build 
up on the surface of heart valve tissue and allow for colonization by staphylococci 
and streptococci.  Colonization encourages further damage and inflammation of 
the heart tissue and the deposition of additional layers of fibrin.  Over time, a 
calcified lesion is formed in which bacterial cells exist as a hardy biofilm and are 
protected from leukocytes by the layers of fibrin, secreted bacterial EPS 
components, and fibroblasts.  In addition, it is thought that the turbulent 
environment near heart valves encourages the deposition of additional EPS on the 
part of the bacteria due to increased mechanical stress that encourages phenotypic 
adaptation. 
The lung colonization of patients with cystic fibrosis is another example of 
an environment in which bacteria frequently cause persistent infections as 
biofilms (Hall-Stoodley et al. 2004).  In this disease, recessive mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene causes 
dysfunctional electrolyte secretion and absorption.  The respiratory system’s 
mucous becomes thick as a result as clearance by ciliated epithelial cells in the 
lungs is impaired, facilitating chronic infection.  P. aeruginosa is the most 
common cause of persistent infection in CF lungs and may adhere to lung 
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epithelial cells with the help of the thick mucus, which it may use as an EPS 
scaffold (Worlitzsch et al. 2002).  Another hypothesis is that inflammation of lung 
epithelial cells may allow adherence.  P. aeruginosa biofilm formation also 
coincides with the development of antibiotic resistance (John et al. 1999).  
Considering that the majority of clinically relevant human pathogens form 
biofilms, that biofilm formation significantly reduces the treatability of bacterial 
infections, and that antibiotic resistance is already developing at an alarming rate, 
the necessity to invest in this area of research is clear. 
 
Ways to eliminate biofilms 
Infections caused by bacteria in the biofilm mode of growth are 
notoriously difficult to eradicate and the most common control strategies are often 
insufficient.  Antibiotics are the most-often turned to method of treating bacterial 
infections, but are less than ideal because of broad damage to host microbiota.  To 
further compound this problem, many notable biofilm formers that are common 
human pathogens are resistant to the most commonly used antibiotics.  Biofilms 
can also create microenvironments of low pH and high metal ion concentrations, 
which can inactivate antibiotics.  Antibiotic treatment is usually completely 
ineffective as a means of combating medical implant device infection.  In these 
cases, it is often necessary to surgically excise the device in order to control the 
bacterial load within the body. It is clear that additional ways of treating biofilm 
infections are necessary. 
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Since adherence to a surface is an essential first step in biofilm formation, 
many studies have focused on ways to prevent adherence of bacterial cells to host 
cells or to abiotic surfaces (Kostakioti 2014).  Efforts to prevent adherence of 
uropathogenic E. coli (UPEC) to the urinary tract have included the development 
of compounds that interfere with the adherence or assembly of type 1 pili, which 
are the primary mediator of UPEC adherence.  Crystal structures of the FimH 
adhesin (utilized in type 1 pili for adhesion) bound to mannose have been used to 
design mannosides which fit the FimH binding pocket and competitively inhibit 
FimH binding to its receptor, thus preventing UPEC biofilm formation.  
Optimized mannosides have also been shown to be effective in reducing pre-
formed biofilms in vitro and in vivo (Cusumano et al. 2011).  Mannosides also 
have no effect on cell growth and are purely anti-adherence.  This type of 
treatment may be useful because of the reduced likelihood of the development of 
resistance.  Another example of this type of potential therapeutic involves using 
exopolysaccharides of one bacterial species to prevent the formation of biofilms 
of another species (Qin et al. 2009).  In addition, genetic studies have identified 
possible means of interfering with biofilm formation signal transduction cascades 
(Njoroge and Sperandio 2009). 
Bacteriophage are promising as antibiofilm agents because they are 
abundant and easy to grow, typically have narrow host ranges (the normal flora in 
humans would likely be unaffected), and low dosages would likely be sufficient 
for treatment because of their self-replicating nature (Kostakioti et al. 2014; 
Donlan 2009).  Phages are often adapted to infect stationary phase bacterial cells 
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and many encode proteins that are specifically used to degrade the EPS matrix to 
allow access to their bacterial hosts.  Transfer of virulence genes is minimized by 
using exclusively lytic phage and resistance to phage infection is often mitigated 
by phages’ high mutation rate and ability to co-evolve with its host.  
Bacteriophage products such as tail spike proteins and lysins can also be used 
separately as anti-biofilm agents. 
Silver and gold nanoparticles coated onto medical devices have also been 
proposed as effective antimicrobial agents.  Silver has been used as an 
antimicrobial for hundreds of years and is toxic to bacteria due to thiol-group 
reactivity with enzymes, causing inhibition of DNA replication, protein 
expression, and metabolism (Chen and Schluesener 2008).  The positively 
charged ions interact with negatively charged bacterial membranes and are 
imported into the cell.  While the use of silver and gold as antimicrobials was 
discouraged for many years due to toxicity of the metals to humans, 
nanotechnology has allowed the creation of very small particles that allow for 
intimate interactions with bacterial membranes without being toxic to humans.  
Silver nanoparticles have been shown to inhibit biofilms of P. aeruginosa, 
Staphylococcus aureus, and Staphylococcus epidermidis (Kalishwaralal et al. 
2010; Secinti et al. 2011). 
Antimicrobial peptides are produced by the innate immune system and are 
possible antibiofilm agents as well as alternatives to antibiotics due to activity 
against many strains of multidrug resistant (MDR) bacteria (Yang et al. 2002).  
Some cathelicidins (the most well-studied group of antimicrobial peptides) are 
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very effective at inhibiting biofilm formation and also dispelling existing biofilms 
formed by P. aeruginosa cells isolated from cystic fibrosis patients (Pompilio et 
al. 2011).  Some peptides are lytic and are promising antibiofilm agents.  The lytic 
peptide PTP-7 remains active in acidic and metal-rich environments (which is 
often the environment of S. aureus biofilms), is capable of deeply penetrating into 
biofilm structures, and was capable of killing 99.9% of biofilm bacteria (Kharidia 
and Liang 2011). 
Some molecules are produced by biofilm-forming bacteria specifically to 
mediate dispersal and allow for the colonization of new environments.  These 
products can be utilized as anti-biofilm agents by applying them exogenously.  D-
amino acids, which disperse S. aureus, P. aeruginosa, and possibly other 
biofilms, work by disrupting the localization of adherence proteins to the bacterial 
cell surface (Kolodkin-Gal et al. 2010).  Nonspermidine is another biofilm-
disassembly molecule in B. subtilus that targets the EPS and is effective in 
treating B. subtilis, S. aureus, and E. coli pellicle biofilms (biofilms at the air-
liquid interface) (Kolodkin-Gal et al. 2012).  Bacteria also produce proteins for 
the purpose of cell dispersal which can be used to the same end. 
Many enzymes are capable of degrading the various components of 
biofilm EPS.  Enzymes that cleave the glycosidic bonds within biofilm 
exopolysaccharides (“EPS depolymerases”) have been shown to be efficacious in 
dispersing biofilms (Kaplan et al. 2003; Bartell et al. 1969; Ghalambor et al. 
1971; Hughes et al. 1998; Kassa and Chhibber 2012).  As the polysaccharide 
“glue” that holds the biofilm together is broken up, individual cells are separated 
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from the bulk biofilm and diffuse into the surrounding medium, where they are 
much more accessible to antibiotics and the immune system.  Dispersin B (DspB) 
is a glycoside hydrolase produced by Actinobacillus actinomycetemcomitans that 
is produced to mediate biofilm dispersal (Kaplan et al. 2003).  As a β-1-6-N-
acetylglucosaminidase, it is effective against biofilms that contain polymers of N-
acetylglucosamine, or PNAG.  This includes S. aureus, S. epidermidis, and E. 
coli.  The effectiveness of DspB in treating S. epidermidis biofilms is illustrated in 
Figure 1-3.  Enzymes that target other parts of the biofilm matrix can also be 
effective in breaking up biofilms.  DNase I can prevent Staphylococcus and 
Enterococcus biofilm formation by digesting the extracellular DNA (eDNA) 
present in the biofilms of these pathogens (Guiton et al. 2009).   
As already mentioned, biofilms often contain metal cations that play a role 
in maintaining EPS integrity.  Metal chelators, therefore, are an attractive 
possibility as antibiofilm agents, especially in species in which metal ions play an 
especially prominent role in biofilm integrity.  EDTA has been used to treat as 
well as prevent biofilm formation in P. aeruginosa and staphylococcal species 
(Bookstaver et al. 2009). 
It is possible to engineer materials used for medical devices so as to 
discourage bacterial adherence and colonization (Desrousseaux et al. 2013).  In 
general, bacteria adhere more effectively to hydrophobic surfaces than 
hydrophilic surfaces.  As a result, hydrophilic materials such as hydrogels 





Figure 1-3: Dispersin B and S. 
epidermidis biofilms (A) Polystyrene rods 
stained with crystal violet. Rods were 
incubated in broth containing S. epidermidis 
strain NJ9709 (rods 1 to 3) or in 
uninoculated broth (rod 4). Prior to staining, 
rod 1 was mock treated, rod 2 was treated 
with DspB, and rod 3 was sonicated. (B) 
The bacteria remaining attached to the 
polystyrene rods after mock treatment and 
treatment with DspB were removed by 
sonication and enumerated by plating of 
serial dilutions on agar. Values indicate 
mean numbers of bacteria per rod for 
triplicate rods. (C) Polyurethane catheters 
were incubated in broth containing S. 
epidermidis strain NJ9709 and then mock 
treated (left catheter) or treated with DspB 
(right catheter). Catheters were then rinsed 
and stained with methylene blue. (D) Teflon catheters were treated as described for panel (C), 
except that bacteria were stained with crystal violet. (E) Polyurethane catheters were precoated 
with PBS (left catheter) or PBS plus DspB (right catheter), rinsed with water, and then incubated 
in broth containing S. epidermidis strain NJ9709 for an additional 6 h. Catheters were then rinsed 
and stained with methylene blue. (F) Teflon catheters were treated as described for panel (E), 






materials (Banerjee et al 2011).  Materials can be modified by the addition of 
polar molecules such as heparin and hyaluronic acid in order to make them more 
hydrophilic (Carlson et al. 2004).  Another way of designing adhesion-resistant 
biomaterials involves minimizing the number of surface contacts that bacteria can 
make.  This has been done by grafting long-chain polymers onto the surface of 
materials to make brush-like structures that use steric hindrance to minimize 
covalent interactions between the material and the bacterial cells (Banerjee et al. 
2011).  Nanotechnology has also been employed to create porous or “spiky” 
materials that similarly limit the number of contacts between bacteria and the 
material surface (Puckett et al. 2010).  In addition, anti-biofilm molecules in some 
cases have been attached to a material in order to prevent biofilm formation.  An 
example is the coating of polyurethane (a material commonly used in medical 
catheters) with DspB to prevent S. epidermidis biofilm formation (Donelli et al. 
2007). The use of natural products as biofilm antagonists has been explored due to 
the increased incidence of antibiotic resistance and a general trend in the 
American public towards more natural remedies (Taraszkiewics et al. 2013).  In 
addition, they are often easy and inexpensive to produce.  Many plant extracts 
have been tested against a variety of bacterial biofilms, the results being reviewed 
in (Taraszkiewics et al. 2013).  One noteworthy example is that of Allium sativum 
extract (fresh garlic extract or FGE).  Preventative use of 35 mg/ml FGE for 14 
days in a mouse model resulted in 1,000-fold fewer bacterial cells than control 
mice when exposed to P. aeruginosa (Harjai et al. 2010). 
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Biofilms can be disrupted by chemical or physical methods. In fact, 
surgical debridement of a wound is not only a way to remove dead or diseased 
tissue, but it is the best way to mechanically disrupt biofilms.  However, the 
frequency of debridement is limiting and many other harsh methods to disrupt 
biofilms (i.e., extreme heat, pH conditions, abrasion, etc.) are often not 
compatible with biological systems such as wounds. 
The complex structure of bacterial biofilms includes many 
macromolecules.  As has been described, the specific composition of the EPS of 
biofilms of one species is usually quite different from other species, even if they 
are closely related.  In addition, the EPS of biofilms of just one species often 
contains many different components.  In order to design treatments for biofilm-
related infections, understanding the composition of a biofilm’s EPS can be very 
useful.  This is the subject of Chapter 2 (Purification and Characterization of 




The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacteriaceae species) are common sources of nosocomial (hospital-
acquired) and war-wound infections and represent a significant threat to public 
health due to their propensity for innate antibiotic resistance (Boucher et al. 2009; 
Calhoun et al. 2008).  In addition, they readily form biofilms on indwelling 
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medical devices, such as catheters and prosthetic heart valves.  S. epidermidis, 
while not technically an ESKAPE pathogen, is closely related to S. aureus and is 
also a formidable pathogen. 
 
Enterococcus faecium 
 E. faecium is a commensal in human digestive tracts that is also an 
important cause of opportunistic infections, such as bacteremia, endocarditis, and 
urinary tract infections (Guiton et al 2009).  Its ability to form biofilms is a 
significant contributer to its virulence and it possesses several virulence factors 
related to biofilm formation (e.g. Fsr, GelE, SprE, and the autolysin AtlA).  These 
proteins all contribute to cell lysis and reflect the large role that eDNA plays in E. 




Staphylococcus aureus is one of the most prevalent causes of hospital-
aquired infections, whereas its close relative, Staphylococcus epidermidis, is the 
most prevalent colonizer of medical implant devices (Campoccia et al. 2013) and 
is a major colonizer of the skin of almost every human (Otto 2012).  While it 
lacks the many toxins that S. aureus utilizes to cause serious illness and is non-
invasive, it is more than capable of acting as a potent opportunistic pathogen in its 
own right.  Most diseases caused by S. epidermidis are chronic, medical device-
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related infections that begin by the introduction of a contaminated medical device 
(such as a catheter or artificial joint) to the host’s body (Otto 2012). 
Many S. epidermidis virulence factors are related to biofilm formation.  As 
a biofilm growing on the surface of medical devices, its resistance to clearance by 
the immune system and antimicrobials contributes to the chronic nature of its 
infections and the need for prolonged antibiotic therapy.  In many cases, it is 
necessary to completely remove the device.  The widespread presence of 
antibiotic resistance genes in S. epidermidis increases the number of untreatable 
cases that require device removal.  Antibiotic resistance is usually due to the 
presence of the mecA gene which encodes for a protein that confers methicillin 
resistance.  Polysaccharide intercellular adhesin (PIA) is the main constituent of 
S. epidermidis biofilm EPS and consists of long chains of β-1,6-linked N-
acetylglucosamine with partially N-deacetylated amine groups.  It is also known 
as poly-N-acetylglucosamine (PNAG) and is usually greater than or equal to 130 
residues. 
S. epidermidis has several microbial surface components recognizing 
adhesive matrix molecules (MSCRAMMs), which are proteins used for 
attachment to tissues and other protein-covered surfaces.  These surfaces can 
include fibrinogen, collagen, and fibronectin. Embp is an example of a S. 
epidermidis MSCRAMM.  It is necessary and sufficient for protein-dependent 
adherence to fibronectin.  Techoic acid is another biofilm-related virulence factor 
that is present in all Gram-positive bacteria and assists in S. epidermidis 
pathogenesis, adhesion, physiology, colonization, and inflammation induction.  
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Poly-γ-glutamic acid (PGA) is a virulence factor that is important for immune 
evasion, whereas another group of molecules used in pathogenesis called phenol-
soluble modulins (PSMs) are often cytolytic and pro-inflammatory. 
 
Klebsiella pneumoniae 
K. pneumoniae frequently causes urinary tract, respiratory tract, and blood 
infections (Lery et al 2014).  The K. pneumoniae capsule exists in over 75 
variations/serotypes and is an important factor in immune evasion.  In addition, 
biofilm formation is aided by genes encoding for the synthesis and transport of 
the PGA polysaccharide (polyglutamic acid) and for YidA, which is thought to 




 A. baumannii is an increasingly important pathogen that causes 
pneumonia, bacteremia, meningitis, and urinary tract infections (Choi et al 2009).  
A. baumannii virulence factors include a pilus and PNAG producing proteins, all 
of which are involved in biofilm formation.  A. baumannii also utilizes Omp38, an 
autoinducer synthase, and a siderophore-mediated iron acquisition system to 





 P. aeruginosa is a common human opportunistic pathogen that is capable 
of thriving in a wide range of environments.  Its resilience often results in chronic 
infection and it is the most commonly recognized pathogen associated with 
chronic pneumonia in the lungs of cystic fibrosis patients (Ryder et al 2007, Mann 
and Woziak 2011).  P. aeruginosa is also capable of producing several biofilm-
associated polysaccharides, including alginate, Pel, and Psl (see Figure 1-4A).   
Alginate, while not essential for biofilm formation, confers considerable 
resistance properties and confers the “mucoid” phenotype associated with 
pseudomonal infections in cystic fibrosis patients (Mann and Wozniak 2011).  Psl 
is mannose- and galactose-rich and is thought to serve as a major scaffold that 
crosslinks P. aeruginosa biofilm components.  The structure of Pel, while not 
fully known, is rich in glucose.  Pel is essential for the formation of pellicles in P. 
aeruginosa, which are biofilms at the air-liquid interface. 
 
Enterobacteriaceae species 
 The Enterobacteriaceae is a large family of Gram-negative bacteria that 
includes pathogens such as Salmonella, E. coli, Y. pestis, Shigella, Enterobacter, 
and others.  E. coli is probably the most studied member of this family and can 
cause food-borne and other infections (Whitfield 2006).  While much is known 
about its capsular polysaccharides, little is known about other polysaccharides 
that may play a role in biofilm formation.  Capsular polysaccharides include O 
antigens, K antigens, enterobacterial common antigen, and colonic acid, also 
known as M antigen (see Figure 1-4B).  In addition to other toxins that are 
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present in other serotypes, E. coli serotype O157:H7 produces Shiga toxin, which 
causes severe, bloody diarrhea (Biscola et al 2011).  This strain is of particular 
clinical relevance because of its ability to cause severe diseases such as 





















Figure 1-4: P. aeruginosa and E. coli-produced exopolysaccharides.  (A)  Pseudomanal 
exopolysaccharides include Psl, alginate, and Pel.  The structure of Pel is not shown because it is 
not known (Mann and Wozniak 2012).  (B)  Colanic acid is a commonly-produced extracellular 




Purification and Characterization of Biofilm-Associated EPS 
Exopolysaccharides from ESKAPE Organisms and Other 
Pathogens 
 
Patrick M. Bales1, Emilija Miljkovic Renke1, Sarah L. May1, Yang Shen1, & 
Daniel C. Nelson1,2 
 
1Institute for Bioscience and Biotechnology Research, University of Maryland, 
Rockville, Maryland, United States of America, 2Department of Veterinary 
Medicine, University of Maryland, College Park, Maryland, United States of 
America 
 
This chapter has been published as follows: 
 
Purification and Characterization of Biofilm-Associated EPS Exopolysaccharides 
from ESKAPE Organisms and Other Pathogens. 
Bales PM, Renke EM, May SL, Shen Y, Nelson DC. 








In bacterial biofilms, high molecular weight, secreted exopolysaccharides 
can serve as a scaffold to which additional carbohydrates, proteins, lipids, and 
nucleic acids adhere, forming the matrix of the developing biofilm. Here we 
report methods to extract and purify high molecular weight (>15 kDa) 
exopolysaccharides from biofilms of eight human pathogens, including species 
of Staphylcococcus, Klebsiella, Acinetobacter, Pseudomonas, and a toxigenic 
strain of Escherichia coli O157:H7. Glycosyl composition analysis indicated a 
high total mannose content across all strains with P. aeruginosa and A. 
baumannii exopolysaccharides comprised of 80-90% mannose, K. 
pneumoniae and S. epidermidis strains containing 40-50% mannose, and E. 
coli with ∼10% mannose. Galactose and glucose were also present in all eight 
strains, usually as the second and third most abundant carbohydrates. N-acetyl-
glucosamine and galacturonic acid were found in 6 of 8 strains, while arabinose, 
fucose, rhamnose, and xylose were found in 5 of 8 strains.  
For linkage analysis, 33 distinct residue-linkage combinations were 
detected with the most abundant being mannose-linked moieties, in line with the 
composition analysis. The exopolysaccharides of two P. aeruginosa strains 
analyzed were consistent with the Psl carbohydrate, but not Pel or alginate. The S. 
epidermidis strain had a composition rich in mannose and glucose, which is 
consistent with the previously described slime associated antigen (SAA) and the 
extracellular slime substance (ESS), respectively, but no polysaccharide 
intracellular adhesion (PIA) was detected. The high molecular weight 
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exopolysaccharides from E. coli, K. pneumoniae, and A. baumannii appear to be 
novel, based on composition and/or ratio analysis of carbohydrates. 
 
Introduction 
Microorganisms that infect humans differ in mechanisms of pathogenesis, 
virulence factors, and antimicrobial resistance profiles. However, one common 
trait shared by most is the ability and propensity to form biofilms (National 
Institutes of Health 2002). Along with upregulation of adhesins, phenotypic 
changes cause bacteria to secrete high molecular weight exopolysaccharides 
during conversion from planktonic to biofilm modes of growth (Crawford et al. 
2008; Danese et al 2000; Kaplan et al 2004, Shemesh et al 2007). These 
exopolysaccharides can make up a crucial part of the extracellular polymeric 
substance (EPS) associated with biofilm development that serves to cement whole 
bacterial populations to a surface rather than enclosing individual 
cells (Sutherland 2001). Also included in the EPS are proteins, secreted nucleic 
acids, humic substances, and metal ions. Together, the EPS protects biofilm 
bacteria from environmental stress (Hall-Stoodley et al 2004; Kives et al 2006). 
The role of the EPS in pathogenesis has been studied in many organisms 
where the biofilm mode of growth has been shown to allow for increased 
resistance to antibiotic treatment, the immune response, and nutrient-limiting 
conditions within the host, promoting long-term persistence (Sandal et al. 2011). 
Biofilm formation on medical implant devices such as catheters and mechanical 
heart valves is also a major problem that is closely tied to the adhesion- and 
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resistance-related abilities granted them by the ability to synthesize and secrete 
exopolysaccharides (Flemming and Wingender 2010; Lewis 2001; Tsuneda et al. 
2003) Human pathogens associated with biofilm development include species of 
Enterococcus faecalis, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These 
“ESKAPE” pathogens are the leading causes of nosocomial infections (Boucher 
et al. 2009; Revdiwala et al 2012) and are so-named to emphasize their ability to 
“escape” the effects of antimicrobial treatment due to acquisition of resistance 
genes as well as formation of biofilms. 
While surface-associated exopolysaccharides and capsules play a role in 
both extracellular and intracellular adherence during the conversion from 
planktonic to biofilm growth, our interests focus on the secreted 
exopolysaccharides, particularly the high molecular weight exopolysaccharides 
that are believed for form the “backbone” of the EPS to which proteins, nucleic 
acids, and capsular polysaccharides adhere (Sutherland 2001; Matsukawa 2004) 
While there are many protocols in the literature for isolation of capsular 
polysaccharides or for the extraction of total bacterial EPS, only a few have 
attempted to fractionate exopolysaccharides by size (Sea et al. 2011) and none 
have been specifically tailored for the isolation of high molecular weight 
backbone exopolysaccharides from biofilms. Bulk EPS extraction requires 
methods that physically break up the biofilm matrix such as ultrasonication or 
EDTA, which promotes EPS separation by chelating cations that are thought to 
crosslink polysaccharide chains within the EPS. The use of glutaraldehyde or 
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formaldehyde is also common to fix bacterial cells to prevent contamination via 
cell lysis during the extraction steps (Azeredo et al. 1999; Liu and Fang 2002). 
Once the bulk EPS is extracted, the polysaccharide fraction must be separated 
from DNA, proteins, and lipids. Oliveira and colleagues successfully utilized 20% 
trichloroacetic acid (TCA) for the precipitation of proteins from the EPS (Oliveira 
et al. 1999), whereas Sutherland used ethanol to precipitate the polysaccharide 
fraction (Sutherland and Wilkinson 1965). Similar protocols have also included 
the use of NaOH to promote dissociation of acid groups within the EPS for 
increased solubility, cation exchange chromatography, differential centrifugation, 
and selective dialysis (Sandal et al. 2011; Anderson 2009; Comte et al. 2007; Pan 
et al. 2010).  
Our laboratory has combined portions of the above protocols and added a 
size exclusion chromatography step to produce an effective method of purifying 
high molecular weight EPS exopolysaccharides. We then apply this methodology 
to biofilms of eight medically important pathogens, including several 
representative ESKAPE organisms, as well as a methicillin-
resistant Staphylococcus epidermidis strain and a toxigenic strain of Escherichia 
coli O157:H7, both of which are known biofilm producers. Finally, we 
characterized the resulting EPS exopolysaccharides by composition and linkage 
analysis. 
Exopolysaccharide purification was done by Emilija Miljkovic Renke and 
Patrick Bales.  Composition and linkage analysis was done by the Center for 
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Complex Carbohydrate Research (Athens, GA).  Lectin staining and confocal 
laser scanning microscopy was done by Patrick Bales and Yang Shen. 
 
Materials and Methods 
 
Bacterial strains and growth conditions 
Unless otherwise indicated, all reagents were purchased from Thermo-
Fisher Scientific and were of the highest purity available. S. epidermidis strain 
NRS-101 was obtained from the Network on Antimicrobial Resistance in S. 
aureus (NARSA). All other strains were purchased from the American Type 
Culture Collection (ATCC). These include two P. aeruginosa strains, 700829 and 
700888, both known biofilm production strains; two K. pneumoniae strains, 
700603, a multi-drug resistant strain and 700831, a biofilm strain; two A. 
baumannii strains, BAA-1878 and BAA-1605, a multi-drug resistant strain; and 
one E. coli strain, 43894, a toxigenic O157:H7 serotype. S. epidermidis strain 
NRS101 was grown in brain-heart infusion media, K. pneumoniae strain 700603 
was grown in Luria broth, and all other strains were grown in tryptic soy broth. 
Glycerol stocks of all strains were stored at −80°C. Biofilms grown for EPS 
purification were prepared by inoculating 20 ml of overnight culture into 400 ml 
of fresh media in a 1.5 L Fernbach flask to provide a large surface area for biofilm 
adherence. Biofilms were grown at 37°C without shaking for 4–5 days until a 





After development of a mature biofilm, 60 µl of formaldehyde (36.5% 
solution) was added to each 10 ml of sludge to fix the cells and prevent cell lysis 
during subsequent steps. The formaldehyde-sludge mixture was incubated at room 
temperature in a chemical hood with gentle shaking (100 rpm) for 1 hour. Four ml 
of 1 M NaOH was added for each 10 ml of sludge and incubated at room 
temperature, with shaking, for 3 hours to extract EPS. Cell suspensions were then 
centrifuged (16,800×g) for 1 hour at 4°C. The supernatant containing soluble EPS 
was filtered through a 0.2 µm filter (Corning) and dialyzed against distilled water 
using a 12–14 kDa molecular weight cut-off (MWCO) membrane for 24 hours at 
25°C. 
 
Purification of exopolysaccharides 
TCA was added (20% w/v) to extracted EPS solutions on ice to precipitate 
proteins and nucleic acids. After 30 minutes, the solution was centrifuged 
(16,800×g) for 1 hour at 4°C, the supernatant was collected, and 1.5 volumes of 
95% ethanol was added and the mixture was placed at −20°C for 24 hours to 
precipitate exopolysaccharides away from lipids. The solution was then 
centrifuged (16,800×g) for 1 hour at 4°C and the exopolysaccharide pellet was 
resuspended in Milli-Q water and dialyzed against the same for 24 hours at 4°C 
using a 12–14 kDa MWCO membrane to remove low molecular weight 
impurities and the remaining retentate was lyophilized overnight. The lyophilized 
powder was then resuspended in 5–10 ml of phosphate buffered-saline (pH 7.4) 
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and purified on a 26/60 S-200 gel filtration column (GE Healthcare) using an 
AKTA FPLC system (GE Healthcare) that had been calibrated with gel filtration 
standards (Bio-Rad) to generate a standard curve of apparent molecular mass vs. 
retention volume. Fractions were tested for the presence of carbohydrates by the 
phenol-sulfuric acid method of DuBois as previously described (1956) and only 
high molecular weight fractions, defined as >15 kDa, containing carbohydrates 
were pooled, dialyzed against Milli-Q water to remove PBS, and lyophilized a 
final time for subsequent composition and linkage analysis. 
 
Composition and linkage analysis 
Carbohydrate composition and linkage analysis was performed at the 
Complex Carbohydrate Research Center (Athens, GA) as previously 
described (Merkle and Poppe 1994; York et al. 1986). Briefly, for glycosyl 
composition analysis, an aliquot (∼500 µg) was taken from the purified EPS 
exopolysaccharide sample and added to a separate tube with 20 µg of inositol as 
an internal standard. Methyl glycosides were then prepared from the dry sample 
by methanolysis in 1 M HCl in methanol, followed by re-N-acetylation 
with pyridine and acetic anhydride in methanol for detection of amino sugars. The 
sample was then per-O-trimethylsilylated (TMS) by treatment with Tri-Sil 
(Pierce). Combined gas chromatography/mass spectrometry (GC/MS) analysis of 
the TMS methyl glycosides was performed on an Agilent 6890N GC interfaced to 
a 5975B MSD (mass selective detector), using a Supelco EC-1 fused silica 
capillary column (30 m×0.25 mm ID). For glycosyl linkage analysis, an aliquot 
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(∼500 µg) was taken from the purified EPS exopolysaccharide sample and 
suspended in ∼300 µl of dimethyl sulfoxide and placed on a magnetic stirrer for 2 
days. The sample was then permethylated by the method of Ciukanu and 
Kerek (1984), hydrolyzed for 2 hours with 2 M trifluoroacetic acid in a sealed 
tube at 121°C, reduced with NaBD4, and acetylated using acetic 
anhydride/pyridine. The resulting partially methylated alditol acetates were 
analyzed by GC/MS as described above.  No replicates were done for 
exopolysaccharide composition or linkage analyses. 
 
Biofilm microscopy 
Biofilms were grown in two-well chamber slides (Lab-Tek) with 1 ml of 
tryptic soy broth for 1 or 3 days. Biofilm wells were washed 2X with PBS and 
then stained with 5 µg of the FITC-labeled Hippeastrum hybrid lectin (HHA) 
from Amaryllis (EY Labs) and Hoechst 33342, a nucleic acid stain (Invitrogen), 
in PBS for 1 hour at room temperature. After incubation, the wells were again 
washed 2X with PBS, chambers were removed from the glass slide, and biofilms 
attached to the slides were imaged by an Eclipse 80i fluorescent microscope 
workstation (Nikon) or an LSM710 laser scanning confocal microscope 
workstation (Zeiss) as previously described (Strathmann et al. 2002). NIS-
Elements (Nikon) or ZEN (Zeiss) software packages were used for image 
analysis. 
 





A schematic of the protocol we developed to purify EPS 
exopolysaccharides from biofilms is shown in Figure 2-1. This methodology 
incorporates into one protocol many extraction and purification steps successfully 
demonstrated by others (Azeredo et al. 1999; Liu and Fang 2002; Oliveira et al. 
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Figure 2-1: Diagram of exopolysaccharide purification. Depending on strain, yields range 
from 2– 15 mg of purified polysaccharide per starting 1.2 L of sludge.  Work done by Patrick 
Bales and Emilija Renke. 
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1999; Sutherland and Wilkinson 1965; Anderson 2009; Comte 2007; Pan et al. 
2010), along with selection steps for high molecular weight for 
exopolysaccharides (i.e.>15 kDa) through use of large pore dialysis and gel 
filtration. As detailed by specific examples in the sections below, our protocol did 
not result in isolation of surface-associated or capsular polysaccharides, indicating 
that the methods were specific for secreted exopolysaccharides. Additionally, the 
protocol was robust, allowing us to successfully extract EPS exopolysaccharide 
from all eight bacterial strains representing five species.  Our yields ranged from 
2–15 mg of purified EPS exopolysaccharide for each strain from 1.2 L of biofilm 
culture (three Fernbach flasks, each containing 400 ml of bacteria). This is lower 
than yields reported by other methods, but is most likely due to our selection of 
only the high molecular weight exopolysaccharide that forms the EPS backbone, 
which excludes lower molecular weight exopolysaccharides and oligosaccharides 
that would co-purify with more crude purification methods. 
 
Composition and linkage analysis 
The glycosyl composition results are summarized in Table 2-1. Across all 
samples, a total of 11 sugars and aminosugars were detected. Notably, mannose 
was found in exopolysaccharides of all strains and was the predominant 
carbohydrate in every strain except E. coli. Indeed, mannose accounted for ∼80–
90% of the total carbohydrate content in P. aeruginosa and A. baumannii species 
and ∼40–50% of the total carbohydrate in K. pneumoniae and S. 
epidermidis species. Galactose and glucose were also found in all eight strains 
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tested and were often ranked as the second or third most abundant carbohydrate. 
Other carbohydrates were also found to be well represented in biofilm EPS 
exopolysaccharides. N-acetyl-glucosamine (GlcNAc) and galacturonic acid 
(GalA) were found in 6 of 8 strains while arabinose, fucose, rhamnose, and xylose 
were found in 5 of 8 strains. In contrast, N-acetyl-galactosamine (GalNAc) was 
only present in the E. coli and S. epidermidis strains and glucuronic acid (GlcA) 
was only found in a single K. pneumoniae strain. 
The glycosyl linkage analysis for EPS exopolysaccharides of all strains is 
summarized in Table 2-2. Across all samples, 33 distinct residue-linkage 
combinations were detected. Consistent with the glycosyl composition results, a 
substantial proportion of the total linkages involved mannose. 2-linked mannose 
(2-Man) and terminally-linked mannose (t-Man) residues were detected in all 
samples, whereas 3-linked mannose (3-Man), 6-linked mannose (6-Man), and 4-
linked glucose (4-Glc) were present in the EPS exopolysaccharide of 7 of the 8 
strains tested. Mannose is also a common branch point for these complex 
structures as 2,6-linked mannose (2,6-Man) was present in 6 strains, 2,3-linked 
mannose (2,3-Man) was present in five strains, 3,6-linked mannose (3,6-Man) 










Table 2-1: Glycosyl composition analysis.  Purified exopolysaccharides were analyzed by gas 














Table 2-2: Glycosyl linkage analysis.  Purified exopolysaccharides were analyzed by gas 





Strain variability within a species 
For each of the three ESKAPE pathogens tested, we analyzed two 
independent strains, which provide a means to assess strain-to-strain variability by 
our methods. In the two P. aeruginosa strains, 700829 and 700888, both were 
found to be >85% mannose by composition, followed by minor constituents of 
glucose, galactose, arabinose, and rhamnose (Table 2-1). Likewise, the major 
linkages of EPS exopolysaccharides from both strains in order were 2,6-Man, t-
Man, 2-Man, and 3-Man (Table 2-2). Similar to the P. aeruginosa results, both A. 
baumannii strains, BAA-1605 and BAA-1878, had a nearly identical composition 
and linkage profile not only to each other, but also to the P. aeruginosa strains. In 
sharp contrast, the two K. pneumoniae strains differed considerably from each 
other. While both strains had high mannose content, the next most abundant 
carbohydrates for strain 700603 were rhamnose, galactose and GlcA. For strain 
700831, those residues were replaced by glucose, rhamnose, and GalA in order of 
importance. 700603 contained 5% GlcA, which was not found in 700831 and the 
latter contained trace amounts of arabinose, fucose, and xylose, which were all 
absent in the former. Thus, in instances where our data differ from historical 
results as described below, we cannot conclude whether these variations are 
attributable to differences in extraction/purification methods, or simply represent 
natural strain to strain heterogeneity within a species as displayed by the two K. 







Of the bacteria studied in this report, biofilms of P. aeruginosa are 
perhaps the best studied. P. aeruginosa produces alginate, a high molecular 
weight, acetylated polysaccharide that is well known for its association with the 
mucoid phenotype common in cystic fibrosis patients. It is composed of β-1,4 
linked L-guluronic and mannuronic acids. In addition, some P. 
aeruginosa species are known to produce Psl, which consists of a repeating 
pentasaccharide of 3 mannose, 1 rhamnose, and 1 glucose (Byrd et al. 2009), and 
Pel, whose exact structure is not completely known, but is reported to have a high 
glucose content (Friedman and Kolter 2004; Friedman and Kolter 2004). Very 
little data are available on the specific strains we tested, 700829 and 700888, 
although 700888 has been sequenced. Its genome possesses all of the genes for 
production of alginate (alg44, alg8, algA-algZ, mucA-mucC) and Psl (pslA-pslM), 
but does not contain the genes for Pel. Since we found the EPS exopolysaccharide 
from both P. aeruginosa strains to be predominantly mannose (∼85–90%) and the 
linkages were chiefly 2-Man, 3-Man, 2,6-Man, and t-Man, we conclude that the 
majority of the EPS exopolysaccharide we observed is consistent with Psl, 
although we cannot rule out additional structures. 
Much is also known about exopolysaccharides of S. epidermidis, in 
particular the NRS-101 strain (a.k.a., RP62A; ATCC 35984) we employed for this 
study. This strain and similar S. epidermidis strains are known to have linear β-
1,6-linked GlcNAc polysaccharides, termed the polysaccharide intercellular 
adhesion (PIA), encoded by the icaADBC operon that mediates intercellular 
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interactions during the biofilm mode of growth (Cramton et al. 1999; Mack et al. 
1994). A separate, galactose-rich capsular polysaccharide adhesion (CPA) is also 
reported to be associated with this strain (Tojo et al. 1988). Christensen and 
colleagues used a mutant of RP62A that lacked the ability to make CPA and 
isolated a high molecular weight exopolysaccharide, called the slime associated 
antigen (SAA), which was found to be primarily glucose (∼59%) (Christensen et 
al. 1990). In contrast, Peters et al. isolated a mannose-rich exopolysaccharide 
from a slime layer of S. epidermidis strain KH11 and called it the extracellular 
slime substance (ESS) (Peters et al. 1987). We did not observe any evidence of 
PIA, which would be expected given the methods we used and the surface 
localization of this polysaccharide. However, our results indicate the high 
molecular weight EPS exopolysaccharide is 52.8% mannose and 35.7% glucose, 
suggesting both SAA and ESS may be present in our sample. Further 
experimentation is required to define the structures of these polysaccharides. 
The polysaccharides of E. coli associated with the capsular O serogroups 
and K-antigens have been studied extensively, but comparatively little is known 
about the non-capsule high molecular weight exopolysaccharides of the 
EPS (Whitfield and Roberts 1999). However, most E. coli strains are known to 
secrete colanic acid, which consists of glucose, galactose, fucose, GlcA, acetate, 
and pyruvate in molar proportions roughly 1:2:2:1:1:1, respectively (Stevenson et 
al. 1996; Sutherland 1969). Moreover, the O157:H7 strain we tested, ATCC 
43894 (a.k.a. CDC EDL 932), has been shown to specifically generate colanic 
acid as its exopolysaccharide (Junkins and Doyle 1992). While our data show this 
47 
 
same strain produces glucose (36.8% of total carbohydrate), fucose, (22.6%), and 
galactose (2.1%) as would be expected for colanic acid, the proportions are not 
consistent with colanic acid and most noticeably, there is a complete absence of 
detectable GlcA. In addition, the presence of GalNAc (26.8%), mannose (9.8%), 
and GlcNAc (1.9%) were unexpected findings, suggesting we isolated a 
previously uncharacterized exopolysaccharide. 
Similar to E. coli, the surface exopolysaccharides (K-antigens) of K. 
pneumoniae, numbering over 80 serovars, have been studied in detail. However, 
there have only been a few attempts to isolate the exopolysaccharide associated 
with biofilm EPS. Rättö and colleagues used an ethanol extraction protocol to 
isolate EPS exopolysaccharide from two similar K. pneumoniae strains and found 
each contained ∼60% mannose, 20% galactose, and 17% GalA (Ratto et al. 
2001). While both of our K. pneumonia strains contained a high percentage of 
mannose as well as significant amounts of galactose and GalA, they also 
possessed considerable rhamnose as well as minor fractions of arabinose, fucose, 
GlcA, GlcNAc, and xylose, depending on strain. This indicates both strains may 
possess EPS exopolysaccharide structures that have not been previously 
characterized. Despite the remarkable heterogeneity in EPS exopolysaccharide 
composition between the two K. pneumoniae strains, it is interesting to note that 
the isolated exopolysaccharides bear no resemblance to the known K-antigens. 
For example, strain 700603 has a K6-type capsule composed of a repeating linear 
polysaccharide of fucose, glucose, mannose and GlcA in equal 
proportions (Elsässer-Beile 1978). In our analysis, the composition of these 
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moieties was 0% fucose, 1.3% glucose, 49.4% mannose, and 5.0% GlcA. Thus, 
we can conclude that our extraction/purification methods are effective at 
separating the high molecular weight EPS exopolysaccharide from capsular 
polysaccharides. 
The EPS exopolysaccharide of A. baumannii is the least studied of all the 
pathogens we tested. Cell-associated poly-β-1,6-linked GlcNAc has previously 
been linked to biofilm development in A. baumannii (Choi 2009), but our protocol 
should not have isolated this surface polysaccharide, which is confirmed by the 
composition results for the two A. baumannii strains we tested, each of which 
showed only ∼1.0% GlcNAc. Crude extraction of EPS exopolysaccharide has 
been performed on other species of Acinetobacter, including A. junii (3 mannose: 
1 galactose: 1 arabinose) (Yaday et al. 2012) and A. calcoaceticus (4 rhamnose: 1 
glucose: 1 glucuronic acid: 1 mannose) (Kaplan et al. 1985) but neither of these 
composition ratios matches the results of our two A. baumannii strains (BAA-
1605; BAA-1878), indicating our exopolysaccharide may be a new finding. 
 
Mannose contribution to EPS 
The most salient finding of our study was the high mannose content of the 
EPS exopolysaccharide across all species and strains (Table 2-1). As such, we 
investigated the binding of the Amaryllis HHA lectin to pathogen biofilms. HHA 
specifically binds α1,3 and α1,6-linked mannose units (Kaku 1990), linkages that 
are common to all 8 pathogens tested (Table 2-2).  When designing lectin binding 
experiments, we focused on biofilms of E. coli strain 43894, since the EPS 
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exopolysaccharide of this strain had the lowest mannose content (9.8%) of all 
strains tested. As can be seen in Figure 2-2A, HHA binding results in an 
extracellular cloud around E. coli cells in 1 day biofilms. When 3 day biofilms are 
viewed by confocal microscopy (Figure 2-2B) HHA only binds to the outer 
surface of the ∼40 µm biofilm, presumably limited in diffusion by the density of 
the biofilm matrix. In the future, specificity of HHA lectin for mannose can be 
verified by immobilizing polymeric mannose on a nitrocellulose membrane and 
then testing for HHA binding by dot blotting.  In contrast to the HHA lectin, 
which is a globular protein composed of 4 subunits, the small molecular weight 
nucleic acid stain penetrates the full thickness of the biofilm maxtrix, staining 
all E. coli cells within the matrix. Given the frequent use of mannose by 
microorganisms as a component of surface antigens or capsule, detection of 
mannose alone cannot be considered diagnostic for the presence of a biofilm. 
Nonetheless, mannose was ubiquitous in the biofilm exopolysaccharides of the 
five species we tested and even the EPS with the lowest mannose content was 
easily visualized by staining with the HHA lectin. Additional lectins or a lectin-
based array (Angeloni et al. 2005) may be useful in future characterization of EPS 
composition from a broad range of organisms. 
Previous studies of extracellular polysaccharide composition have 
detected high levels of mannose as the result of contamination of growth media 
components, specifically mannan from the yeast extract portion of trypic soy 
browth (Pier et al 1983).  While we cannot rule out the possibility of the presence 
of some contaminant mannose in our samples, the large differences between the 
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molar percentage of mannose present in the tested strains suggests that 
contaminants do not play an overwhelming role in this study.  The lowest percent 
mannose makeup is less than 10% whereas the highest is almost 90%.  In the 
future, removing mannose with a mannan-binding column prior to composition 
and/or linkage analysis, as suggested by Pier, et al (1983), may be done to rule out 
the influence of yeast extract contaminants.  In addition, biofilms could be grown 
with chemically defined media lacking mannose.   
 
EPS staining of E. coli strain 43894 biofilms. 
It has long been known that the exopolysaccharide portion of the EPS 
plays a substantial role in bacterial adherence and resistance (Sutherland 2001; 
Hall-Stoodley et al. 2004; Parsek and Singh 2003) and the mannose results above 
suggests there may be commonalities between biofilm EPS that can be exploited 
for diagnostic and/or therapeutic purposes. For example, breaking the most 






Figure 2-2: EPS staining of E. coli strain 43894 biofilms. The FITC-labeled mannose-specific 
HHA lectin was used to stain exopolysaccharides (green) and Hoechst 33342 was used to stain the 
bacterial nucleic acids (blue). (A.) Extracellular green staining of the EPS by FITC-HHA can be 
seen on 1 day old biofilms of E. coli at 200X. Scale bar =5 mm. (B.) Confocal image of 3 day old 
E. coli biofilms at 63X. The large square panel is a plan view looking down on the biofilm. The 
top and right-side rectangular panels are vertical sections representing the XZ plane and YZ plane, 
respectively, at the positions indicated by the colored lines. The biofilm is 40 mm thick (i.e. Z-










effective means of dispersing biofilms and making the subjacent bacteria more 
susceptible to treatment by antibiotics. Notably, bacteriophage have co-evolved 
with natural biofilms of host organisms for billions of years and have developed 
enzymatic domains on tail fiber and tailspike proteins that degrade 
polysaccharides of the EPS and capsule, allowing the phage access to surface 
receptors for infection (Casjens and Thuman-Commike 2011; Sutherland et al. 
2004; Yurewicz et al. 1971). These enzymes, generically termed depolymerases, 
have been shown to degrade exopolysaccharides even in the absence of 
phage (Hughes et al. 1998), although extensive analysis of their specificity and 
utility as anti-biofilm agents has yet to be elucidated. 
Another example of a potential anti-biofilm enzyme is dispersin B (DspB), 
a β-1,6-N-acetyl-glucosaminidase from the bacterium Actinobacillus 
actinomycetemcomitans. First described in 2003 (Kaplan 2003), this enzyme has 
the ability to degrade EPS from Actinobacillus (Kaplan 2004) and S. 
epidermidis (Chaignon 2007; Kaplan 2004) biofilms. While enzymatic digestion 
of the EPS exopolysaccharide is not expected to directly kill bacterial cells, the 
dissolution of biofilms or prevention of future biofilm formation should allow 
bacteria to become re-sensitized to antibiotics and immune system mechanisms 
(i.e., complement, antibodies, phagocytes, etc.) Alternatively, these agents could 
be used to prevent biofilm formation. For example, DspB has been successfully 
incorporated into a polyurethane material, showing that materials, such as medical 
implants, could be engineered with anti-biofilm enzymes to prevent 
colonization (Donelli et al. 2007). 
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Obtaining detailed structural characteristics by NMR for the current set of 
EPS exopolysaccharides in relationship to the composition and linkage data 
generated here will help validate our extraction and purification methods. Further 
characterization of ESKAPE biofilm EPS by the methods we employed here may 
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 Staphylococcus epidermidis is a bacterium that is found on the skin of 
almost all humans but is capable of opportunistic infection (often by colonizing 
medical implant devices).  When it does so, it normally survives by growing as a 
biofilm.  Biofilm-forming bacteria are notoriously difficult to eradicate due to the 
resistance to antimicrobials and other stressors provided by the extracellular 
polymeric substance (EPS).  Polysaccharide intercellular adhesin (PIA) is a major 
constituent of Staphylococcus epidermidis EPS and is made up of partially 
deacetylated β-1,6-N-acetylglucosamine.   
A bioinformatics search of putative hexosaminidases and 
glucosaminidases that may be able to break up S. epidermidis biofilms revealed 
an uncharacterized enzyme produced by Neisseria wadsworthii, henceforth 
referred to as HexNW.  It was found to be active against a synthetic substrate 
containing N-acetylglucosamine and had a Km of 1.1 ± 0.4 mM and a Vmax of 4.0  
± 0.5 pmols/sec, but it did not display activity against chitin-like substrates.  In 
addition, HexNW was found to be highly thermostable by measuring enzymatic 
activity after incubation at various temperatures and by performing circular 
dichroism and differential scanning calorimetry. Finally, HexNW was shown to 
be antagonistic to S. epidermidis biofilms by monitoring the release of amino 
sugars and colony-forming units from the surface of the biofilm.  In addition, a 2-
fold decrease in the minimum biofilm elimination concentration (MBEC) was 
observed when HexNW was used to supplement vancomycin treatment of a 
methicillin-resistant S. epidermidis strain.   
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The only other enzyme that has been studied that is effective against this 
species is dispersin B (DspB), which is homologous to HexNW (63%).  The 
significant differences in amino acid sequence between these proteins as well as 
the thermostability of HexNW makes it promising tool to combat biofilm-related 
infections of S. epidermidis. 
 Identification of HexNW was done by Daniel Nelson.  Synthesis was done 
by Life Technologies.  Expression, purification, and all enzyme activity assays 
were done by Patrick Bales.  Circular dichroism and differential scanning 
calorimetry experiments were done by Ryan Heselpoth. 
 
Background 
While bacterial pathogenesis mechanisms, virulence factors, and 
antimicrobial resistance vary greatly between species, the ability and preference 
to grow as biofilms are common to the vast majority (Hall-Stoodley et al. 2004). 
Biofilms are formed when planktonic bacteria (i.e., free, individual cells) adsorb 
onto a wound surface and form colonies (Hall-Stoodley et al. 2004; Stewart et al. 
2008; Stoodley et al. 2002). Once the colonies become established, genetic 
regulation causes them to secrete high molecular weight carbohydrates (i.e., 
polysaccharides) that serve as the structural backbone for the biofilm. Non-
cellular components and debris, including additional carbohydrates, proteins, 
lipids, and nucleic acids, become entangled in the polysaccharide backbone and 
constitute the “slime” layer of a biofilm which is technically known as the 
extrapolymeric substance, or EPS (Flemming and Wingender 2010).  The EPS is 
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thought to protect the bacteria from antimicrobials, antibodies, and circulating 
immune cells. 
The natural resilience of biofilms along with the rise of antibiotic-resistant 
pathogens illustrates the urgent need for new and innovative ways to treat biofilm-
related infections.  Biofilms are responsible for complications such as secondary 
wound infections, chronic P. aeruginosa infection in the lungs of cystic fibrosis 
patients, and the colonization of medical implant devices.  As an example, 
coagulase-negative staphylococci such as Staphylococcus epidermidis, which are 
typically viewed as less virulent then their coagulase-positive counterparts, 
including S. aureus, are responsible for about 250,000 cases of intravascular 
catheter infections per year with a cost of about $25,000 per case and hospital 
stays exceeding 7 days (Otto 2012). 
Research focused on ways of treating bacterial infections specific to 
biofilm-formers is lacking.  Methods include the use of metal chelators, phages, 
or modifications to surfaces with silver nanoparticles (Bookstaver et al. 2009, 
Bartell et al. 1969, Kalishwaralal et al. 2010).  In addition, proteins that digest 
components of the EPS (EPS depolymerases) can be effective (Hughes et al. 
1998).  As the matrix that encapsulates bacterial cells is degraded, the bacteria in 
the biofilm revert to a planktonic lifestyle and are resensitized to the action of the 
immune system and antibiotics.   
Dispersin B (DspB) is a glycoside hydrolase produced by Actinobacillus 
actinomycetemcomitans that is the only well-studied EPS depolymerase to date.  
It is effective in breaking up biofilms of S. epidermidis which are formed on 
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polystyrene rods, polyurethane catheters, and Teflon catheters (Kaplan et al. 
2004).  In addition, DspB has been found to be effective against other β-1,6-N-
acetylglucosaminine-containing biofilms.  Izano, et al (2008) found that DspB 
prevented biofilm growth in both S. epidermidis and S. aureus when used to 
supplement growth media, while Darouiche and collegues (2009) observed that 
DspB is effective at breaking up and dispersing E. coli biofilms.  Dispersin B has 
also been used in unique applications to prevent and treat biofilms.  It has been 
bound in conjunction with an antibiotic to polyurethane (a common material used 
in intravenous catheters) and is capable of preventing biofilm formation in that 
state. (Donelli et al. 2007). A T7 phage has even been engineered to express 
DspB, which greatly increases the killing ability of the phage towards E. coli 
biofilms (Lu 2007).  A bioinformatics search for additional glucosaminidases 
revealed HexNW, which is the focus of this manuscript.  It is homologous to 
DspB and is equally effective in breaking up S. epidermidis biofilms but has the 
great advantage of being highly thermostable. 
 
Materials and methods 
 
Bacterial strains, growth conditions, and biofilm formation 
 E. coli DH5α was used for cloning and BL21 (DE3) was used for 
expression.  While BL21 (DE3) was used as the expression strain, the expression 
vector (pBAD24) provides an arabinose-activated promoter that is not dependent 
on BL21 (DE3) expression of T7 RNA polymerase.  Biofilms of Staphylococcus 
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epidermidis strain NRS 101, also known as RP62A and ATCC 35984, came from 
the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA).  It 
is a mecA positive, slime positive strain sequenced by TIGR.  For cloning, the 
growth media used was Luria Broth supplemented with ampicillin.  NRS 101 
biofilms were grown for 24 hours at 37°C without shaking.  Plates used for 
biofilm formation included MBECTM biofilm inoculator, physiology and genetics 
panel (Innovotech), CoStar® Corning® CellBIND® Surface 24 well polystyrene 
plates with lids, and NEST 96-well, polystyrene cell culture plates.  
 
Gene synthesis, expression, and purification 
Dispersin B- and HexNW-encoding plasmids (see GeneBank accession 
numbers AAP31025.1 and WP_009115775.1 for corresponding proteins) were 
synthesized using the GeneArt® Gene Synthesis service provided by Life 
Technologies (www.lifetechnologies.com) after codon optimization for E. coli 
expression of BLAST-derived gene sequences.  Depolymerase genes were cloned 
into the pBAD24 vector using restriction sites that were included in the gene 
synthesis.  Also included were sequences encoding N-terminal 6xHis tags.  
Plasmids were transformed into BL21 cells, which were then grown until mid-log 
phase (OD600 1.3-1.7).  Protein expression was induced with 0.25% arabinose and 
cultures were grown at 18°C for 4 hours or overnight.  Depolymerases were 
harvested by centrifugation at 7,000 rpm for 15 minutes, resuspension in 
phosphate-buffered saline (PBS, 50 ml per liter of culture) plus 1 mM PMSF, and 
sonication for 10 min using a sonicator set to 30% duty cycle and level 6 output.  
60 
 
The resulting solution was centrifuged at 13,000 rpm for 1 hr.  The supernatant 
was saved.  Depolymerases were then purified from cell lysate by nickel affinity 
purification using Bio-Scale Mini Profinity IMAC cartridges (Biorad).  After 
loading onto a charged column, the column was washed with 20 mM imidazole, 
20 mM MES pH 6.5, and 1 M NaCl before eluting with 250 mM imidazole. 
 
Enzyme activity assays 
 HexNW and DspB were combined with PBS and 4-nitrophenyl N-acetyl-
D-glucosaminide (pNP-GlcNAc, Sigma) to directly measure enzymatic activity.  
This substrate consists of one N-acetylglucosamine unit and a nitrophenyl group 
(extinction coefficient of 18,600 M-1cm-1, Shibata et al. 1997).  When cleaved, the 
emitted nitrophenyl group can be monitored colorimetrically be measuring 
absorbance at 405 nm.  All reactions were done in NEST polystyrene 96-well 
plates and absorbance read at 405 nm using a Molecular Devices SpectraMax M5 
spectrophotometer.  The predicted molecular weights of HexNW (57.9 kDa) and 
DspB (42.0 kDa) and the reported molecular weight on pNP-GlcNAc (342.3 
g/mol) were used to adjust enzymes to concentrations of 10 µM and to adjust 
pNP-GlcNAc to final concentrations varying from 10 µM to 5 mM.  Unless 
otherwise described, reactions were done in 40 mM boric acid 40 mM phosphoric 
acid buffer (BP buffer) at pH 6.5.  Kinetic assays were done at 20 second intervals 
and with 5 seconds of shaking before readings were taken. Kinetic assays were 
normally done for 30 minutes total.  Enzyme kinetic readings were done using the 
Softmax Pro software version 5.4.1.  Initial velocities were calculated by taking 
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data during time points in which R2 values for all replicas were at least 0.95 and 
were done by observing the change in milli-absorbance units (mAU) at 405 nm 
per minute.   
The velocity at each substrate concentration was calculated by first 
converting from mAU/min to AU/sec.  Using the assumptions of Beer’s law, 
AU/sec was converted to M/sec.  The reaction volume of 200 µl was used to 
convert from M/sec to mol/sec.  The velocity (mol/sec) was therefore calculated 
as follows: V (mol/sec) = (milliAU/min x min/60 sec x AU/1000 milliAU x 1 
cm)/(18,600 M-1cm-1) x (2 x10-4 liters).  The 18,600 M-1cm-1 value is the 
extinction coefficient of the 4-nitrophenoxide released from the substrate at 405 
nm (Shibata, 1996). Maximal velocity Vmax and the Michaelis-Menten constant 
Km were calculated by hyperbolic regression analysis using the program Hyper32.  
Error (standard deviation) was estimated using the average values of triplicate 
reactions and was also calculated by the Hyper32 fitting program.  The turnover 
number, kcat, was calculated as follows: kcat (s-1) = average Vmax/E, where E is the 
mols of DspB or HexNW in the assay.  E was determined by multiplying the 
molar concentration of each enzyme in mol/L times the reaction volume in liters. 
Therefore, at final enzyme concentrations of 10 µM, both DspB and HexNW had 
2 nmols per each 200 µl reaction well in the 96 well plate.  
 
Chitinase experiments 
 HexNW and a chitinase (both at 1 mg/ml) from Streptomyces griseus 
(Sigma) were incubated with a chromogenic chitin substrate, 4-nitrophenyl β-D-
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N, N’, N’’-triacetylchitotriose (Sigma, 1 mg/ml) or buffer for one hour at 37°C.  
Optical density at 405 nm was read as a measure of chitinase activity. 
 
pH profile assays 
 Enzyme activity assays were done as described above, except that the 
concentration of pNP-GlcNAc substrate was always 1 mM while the pH was 
varied.  This substrate concentration was chosen because it is close to the Km 
values of DspB and HexNW and produced a rhobust increase in OD405 at 10 µM 
DspB and HexNW.  The buffer used was 40 mM boric acid 40 mM phosphoric 
acid buffer, which was adjusted to a range of pH values between 3 and 11. 
 
Thermostability assays 
 Thermostability assays were done by incubating enzymes at various 
temperatures for 30 min, putting them on ice for 5 minutes followed by 10 
minutes at room temperature, and then assaying enzymatic activity of the 
enzymes at 10 µM as described above. 
CD experiments were performed on a Chirascan CD Spectrometer 
(Applied Photophysics) equipped with a thermoelectrically controlled cell holder. 
For secondary structure far-UV analysis, the protein was at a 0.1 mg/ml 
concentration in 20 mM sodium phosphate buffer pH 7.0. CD spectra were 
obtained in the far-UV range (190-260 nm) in a 1 mm path length quartz cuvette 
at 1 nm steps with 5 second signal averaging per data point. Spectra were 
collected in triplicate, followed by averaging, baseline subtraction, smoothing and 
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conversion to mean residue ellipticity (MRE) by the Pro-Data software (Applied 
Photophysics). Secondary structure prediction was performed using the 
Provencher and Glockner method provided by DICHROWEB (Provencher and 
Glockner 1981; Whitmore and Wallace 2004). Melting experiments were 
performed by heating the protein at a 1 mg/ml concentration in 20 mM sodium 
phosphate buffer pH 7.0 from 20°C to 95°C at 1°C/min. MRE was monitored at 
222 nm in a 1 mm path length quartz cuvette at 0.5°C steps with 5 second signal 
averaging per data point. The melting data was smoothened, normalized and fit 
with a Boltzmann sigmoidal curve when applicable. The first derivative of the 
melting curve was then calculated to determine the temperature (T1/2) for each 
sample at which the folded and unfolded state of the particular protein species 
was at equilibrium (Falass and Hartgerink 2012). 
 DSC experiments were performed on a Nano DSC Differential Scanning 
Calorimeter (TA Instruments) at a constant pressure of 3 atm.  All samples were 
degassed for at least 20 minutes prior to the experiment. The sample and reference 
cells consist of an optimal operational volume of 0.3 ml and were calibrated with 
equal volumes of 20 mM sodium phosphate buffer pH 7.0 by means of three 
consecutive heating/cooling cycles from 5°C to 105°C and 105°C to 5°C. DspB 
and DspNW were then heated from 5°C to 105°C at a 1°C/min heating rate in 20 
mM sodium phosphate buffer pH 7.0 using a final protein concentration of 1 
mg/ml followed by immediate cooling from 105° to 5°C at 1°C/min. Data 
analysis by means of baseline subtraction and curve fitting was performed by the 
NanoAnalyze software (TA Instruments).  
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Amino sugar assays 
 NRS 101 biofilms were grown for 26 hours, washed twice with water, 
aspirated, and then incubated with 0.25 mg/ml HexNW or boric acid phosphoric 
acid buffer, pH 6.5, for 1 hour at 37°C.  The treatment fluid was then removed 
and spun at 12,000 rpm for 10 minutes.  Supernatant containing released sugars 
(50 µL) was added to 100 µL pentadione solution, boiled for 1 hour, and then 
added to 100 µL of Ehrlich I solution according to the Morgan-Elson method 
(Strominger et al. 1959).  Optical density at 530 nm was then measured to assay 
the presence of amino sugars.  Each sample was performed in triplicate. 
 
CFU release 
 Biofilms were grown as described above.  After treatment with enzyme 
(0.25 mg/ml) or PBS buffer for 1 hour at 37°C, the solution was spun at 12,000 
rpm for 10 minutes and the pellet washed once with sterile TSB.  After 
resuspension in TSB, the cell suspension was serial diluted and plated using 
spread plate technique to estimate the colony forming units released from the 
biofilms as a result of HexNW treatment.  Each sample was performed in 
triplicate.  Percent increase in CFU after biofilm treatment with HexNW was 
calculated by subtracting the CFU value of each replica from the average CFU 
value of mock-treated biofilms, dividing by the mock-treated CFU value, and then 
multiplying by 100.  The standard deviation of all three replicas’ CFU values was 
treated the same as HexNW CFU values (it was subtracted from mock-treated 
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CFU value, divided by the mock-treated CFU value, and then multiplied by 100) 
to give the error shown in the results figure. 
 
Minimum Inhibitory Concentration (MIC) and Minimum Biofilm Elimination 
Concentration (MBEC) Assays 
 For MIC determination, overnight cultures of S. epidermidis NRS 101 
were grown in NEST 96-well plates at 37°C with shaking.  The following day, 
two-fold dilutions of filtered vancomycin were done in another 96-well plate, 
from 64 µg/ml down to 0.125 µg/ml.  Dilutions were done using sterile water.  
Control wells without any vancomycin were also made.  Overnight culture was 
then added to the antibiotic or water-containing wells by pipetting 2 µl of culture 
into each well.  The inoculated plate was then secured in a 37°C shaking 
incubator and allowed to grow overnight.  The MIC is defined as the lowest 
concentration of vancomycin that prevents NRS 101 growth (Sepandj et al. 2004). 
For MBEC determination, biofilms of NRS 101 were grown as described 
above, except in this instance, Innovotech MBECTM biofilm inoculators 
(physiology and genetics panel) were used.  These growth plates are in 96-well 
format and have polystyrene pegs attached to the plate lids such that when placed 
on the tray, the pegs are inserted into each well.  After biofilm growth for 24 hrs 
at 37°C, growth media and planktonic cells were removed by shaking into a pan 
filled with bleach water.  Biofilms on the pegs and tray were washed by dunking 
twice in a separate pan filled with water.  Vancomycin was added to 
concentrations indicated and enzymes were added to a final concentration of 0.05 
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mg/ml.  The lid was replaced onto the tray and allowed to incubate at 37°C for 3 
hours without shaking.  Following incubation, sterile TSB was added to a new 96-
well plate (NEST) and used to wash the pegs by dunking.  TSB (200 µL) was 
added to another new 96-well plate and the lid was placed onto this tray and 
secured with tape.  The plate was then incubated overnight at 37°C.  The next 
morning, growth was observed visually and by measuring optical density of the 
wells at 600 nm using a Molecular Devices SpectraMax M5 spectrophotometer.  
The MBEC is the lowest concentration that results in no growth when treated 




Identification, expression, and purification 
HexNW (NCBI accession number ZP_08938922.1) was identified as a 
possible β-1,6-N-glucosaminidase by performing protein BLAST conserved 
domain searches.  It is produced by the mesophilic skin bacteria Neisseria 
wadsworthii (Wolfgang et al 2011).  This domain is found in glycosyl hydrolase 
family 20 and has a TIM barrel fold (Marchler-Bauer et al. 2013).  It is also 
homologous (63% identity) to the β-N-acetylglucosaminidase domain found in 
DspB (Figure 3-1).  This domain encompasses amino acid residues 12 to 360 of 
this 508 amino acid protein.   The C-terminal end of HexNW lacks homology to 
any particular protein domain, but can be speculated to help confer 
thermostability to the protein (see Future Directions).  In addition, the 8 dispersin 
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B active site residues exactly match the corresponding amino acids  on HexNW in 
terms of identify and spacing (Figure 3-1). 
The gene encoding HexNW was synthesized as a plasmid with codon 
usage optimized for E. coli expression by Life Technologies.  It was expressed in 
BL21 (DE3) cells after cloning into the pBAD24 expression vector, which uses 
arabinose induction.  While it was synthesized with an N-terminal 6xHis tag and 
expressed well, it was necessary to switch the His tag to the C-terminal end of the 
protein to allow for purification using nickel column affinity chromatography 






Figure 3-1: HexNW alignment with dispersin B.  Numbers written represent the amino acid 
residue number of the protein that is named on the same line.  The lines between DspB and 
HexNW lines represent the consensus sequence, with plus symbols (+) indicating residues that are 
not identical but have similar properties.  Residue numbers begin at the N-terminus and continue 
towards the C-terminus.  HexNW is 63% identical to DspB and most alignment is within the β-N-
acetylglucosaminidase domain (DspB amino acids 12-360).  Since HexNW has 508 amino acids, 
there is a significant portion of the C-terminus that does not align with DspB.  Highlighted 







 Due to homology with DspB, a known β-1,6-N-acetylglucosaminidase, 
HexNW was tested for activity against a synthetic substrate: para-nitrophenylated 
N-acetylglucosaminine (pNP-GlcNAc).  HexNW was found to have activity 
against pNP-GlcNAc, cleaving the para-nitrophenol group off of the N-
acetylglucosamine unit to allow for absorbance at 405 nm (see Figure 3-2A).  
This substrate was used as an approximation of the predicted real-world substrate 
of HexNW: poly-N-acetylglucosamine (Figure 3-2B) 
Incubation of HexNW or DspB with pNP-GlcNAc at varying 
concentrations allowed the determination of Km and Vmax values, as shown in 
Table 3-1.  Both enzymes had millimolar affinity for pNP-GlcNAc, although 
comparison of the Km values suggests that DspB binds this subsrate more tightly 
(Km of 0.59 mM vs. 1.13 mM for DspB and HexNW, respectively). Dividing the 
average Vmax values for each enzyme by the amount of enzyme present in each 
well (2 nmoles), yields the kcat, which can be used to calculate the catalytic 
efficiency (kcat/Km) of the enzymes. The DspB kcat/Km value of 6.78 M-1 s-1 is 
consistent with value(s) in published literature.  Fazekas et al. (2012) reported 
values increasing from 2.1 to 8.6 M-1 s-1 depending on whether the substrate was a 
dimer, trimer, tetramer, or pentamer.  Likewise, Manuel et al., (2007) reveals that 
HexNW binds to pNP-GlcNAc about half as tightly as DspB.  HexNW maximum 
velocity (Vmax) is also about half that of DspB, suggesting that HexNW cleaves 
pNP-GlcNAc about half as fast as DspB.  In comparison, HexNW has a kcat/Km 
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value of 1.77 M-1 s-1, indicating similar efficiencies on the synthetic pNP-GlcNAc 
substrate.  Additional studies on oligosaccharides of N-acetylglucosamine are 











Figure 3-2: Reaction of HexNW with pNP-GlcNAc.  HexNW reacts with pNP-GlcNAc 
(reactant) to produce 4-nitrophenol (product), which absorbs light at 405 nm (A).   Also released is 
one unit of N-acetyl-β-D-glucosamine (not shown).  pNP-GlcNAc is similar to PNAG, except 
instead of one GlcNAc unit linked to para-nitrophenol, multiple GlcNAc units are linked at the 




Enzyme Vmax (pmols/sec) 
Km 
 (mM) kcat (s
-1) kcat/Km (M-1 s-1) 
DspB 8.3 ± 0.8 0.59 ± 0.1 4.1 × 10-3 6.78 
HexNW 4.0 ± 0.5 1.1 ± 0.4 2.0 × 10-3 1.77 
 
Table 3-1: DspB and HexNW enzyme kinetics.  Kinetic parameters determined by analysis of 
steady state turnover of pNP-GlcNAc by DspB and HexNW via Michaelis-Menton kinetics.  





Since the substrate used so far consisted of only one GlcNAc unit linked 
to a chromophore, any activity on this substrate can be seen as glucosaminidase 
activity without being able to specify if it is 1,4- or 1,6-glucosaminidase activity.  
Additional experiments were conducted to determine if HexNW acts on 1,4-
linked GlcNAc or 1,6-linked GlcNAc.  A substrate was purchased from Sigma 
and used to treat HexNW and a chitinase control (Sigma).  Chitin consists of 1,4-
linked N-acetylglucosamine, the only other linkage possibility for GlcNAc that is 
β-linked besides 1,6-linked GlcNAc.  The purchased substrate, 4-nitrophenyl β-D-
N, N’, N’’-triacetylchitotriose, consists of three 1,4-linked N-acetylglucosamine 
units and is commonly used to test for chitinase activity.  The results, in Figure 3-
3, show that HexNW does not react with chitin (1,4-linked GlcNAc).  HexNW, 
therefore, is likely a 1,6-N-acetylglucosaminidase, similar to DspB.  The 
relatively high OD405 value of chitinase alone is likely due to the inherent 






Figure 3-3: Chitinase activity.  A Streptomyces griseus chitinase and HexNW were incubated 
with a chromogenic chitin substrate, 4-nitrophenyl β-D-N, N’, N’’-triacetylchitotriose to measure 
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Depolymerase reaction with chitin substrate 
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pH activity profile 
 Having established HexNW as a glucosaminidase, it was subsequently 
tested using the same assay except at a set substrate concentration and varying pH 
values.  This was done because pH is a useful parameter in assessing the ability of 
an enzyme to function in a variety of environmental conditions, which is 
important for protein therapeutics that may be applied in a number of ways 
(topical, ingestion, etc). Figure 3-4A shows that HexNW activity has a pH 
optimum of 6.5, with decreasing enzymatic activity at both higher and lower pH 
values.  It is shown to have near-optimal activity between pH 6 and pH 7.  
Activity sharply drops off below pH 6 and above pH 7. 
 The relatively narrow pH range of HexNW may be related to possible pH 
effects on the substrate and active site residues.  HexNW is likely a glycosyl 
hydrolase family 20 β-hexosaminidase (determined by protein BLAST conserved 
domain searches).  The hydrolysis of this group of enzymes is proposed to involve 
a glutamic acid residue as the proton donor and acceptor and a N-acetyl group on 
the substrate as the nucleophile (see Figure 3-4B).  The transition state is 
stabilized by the carboxyl carbon of an active site aspartate.  The pH profile of 
HexNW is likely dependent on the pKa values of these important functional 
groups. The pH optimum of HexNW is 6.5 while the optimum pH of wild-type 
DspB is 5.8 (Suba et al 2007).  In addition, the effect of pH changes on the para-
nitrophenol group of pNP-GlcNAc (pKa 7.2) likely has some effect on the 
extinction coefficient of pNP-GlcNAc, which may account for some of the 


























HexNW pH Activity Profile 
77 
 
Figure 3-4: HexNW pH effects.  HexNW (10 µM) was added to pNP-GlcNAc (1 mM) in BP 
buffer of various pH values in order to measure the dependence of activity on pH (A).  The 
proposed hydrolysis mechanism of glycosyl hydrolase family 20 is given in (B), in which Glu184 
and Asp183 are active site residues and the substrate (middle) is pNP-GlcNAc (Manuel et al 





 Prior to incubation with pNP-GlcNAc, HexNW was subjected to various 
temperatures for 10 min in order to assess its ability to withstand the unfolding 
effect of heat.  The results, described in Figure 3-5, show that HexNW maintains 
near 100% activity at tested temperatures up to 45°C.  It then shows a reduction in 
activity at temperatures above 50°C with no activity detected at any tested 
temperature which is 60°C or higher.  DspB, on the other hand, starts showing a 
reduction in activity between 30 and 37°C and no activity is observed at tested 
temperatures that are 45°C or higher.  Based on this assay, therefore, HexNW 
unfolds at least 15°C above the melting point of DspB and is substantially more 
thermostable than DspB. 
To further explore the thermostable nature of HexNW, circular dichroism 
(CD) and differential scanning calorimetry (DSC) were performed to estimate the 
melting temperature of HexNW and DspB.  Since the unique CD spectrum of a 
protein is based on secondary structure, measuring a molecule’s CD spectrum 
along a temperature gradient can be used to detect the temperature at which a 
protein unfolds.  Using this method, DspB was found to have a melting 
temperature of 44.4°C whereas HexNW had a melting temperature of 60.3°C (see 
Figure 3-6A).   DSC, on the other hand, measures the molar heat capacity of 
solutions by detecting the amount of heat required to raise the solution by a given 
temperature.  Because organized protein structures have higher heat capacities 
than unorganized structures, DSC is well-suited to detect thermal transitions as a 
protein solution is heated up (thermal transitions representing the unfolding of 
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protein structures).   Using DSC, DspB was found to have a melting point of 
44.25°C and HexNW was found to have a melting point of 58.00°C (Figure 3-
6B).  The melting points were found by observing the first thermal transition, 
which in proteins general corresponds to secondary rather than primary structure 
degradation.  Thus, by multiple methods, the Tm of HexNW is ~15°C greater than 
DspB.  The melting points of all thermal transitions for DspNW and DspB by 
DSC are recorded in Table 3-2.  A summary of the melting point information 






Figure 3-5: Temperature stability.  HexNW and DspB (10 µM) were incubated for 10 min at the 
given temperature before being placed on ice and then allowed to come to room temperature.  
Enzymatic activity was then assayed with 1 mM pNP-GlcNAc.  Activity measurements were done 
for both enzymes at all listed temperatures (activities for both enzymes at 60°C, 65°C, and 70°C 










































Figure 3-6.  CD and DSC melting point analysis.  For CD analysis (A), spectra of DspB and 
HexNW were obtained in the far-UV range and melting was done by heating the proteins 
1°C/minute.  The melting temperature for DspB was 44.4°C and 60.3°C for HexNW.  For DSC 
analysis (B), samples were degassed for 20 min and heated at a rate of 1°C/minute.  The melting 
temperature for DspB was 44.25°C while it was 58.00°C for HexNW.  Colored curves represent 
the overall changes in heat capacity for each sample while the black, dotted curves underneath the 
colored curves represent changes in heat capacity associated with each of 2 thermal transitions that 










DspB 44.25 46.00 234.88 222.51 
HexNW 58.00 59.29 251.54 406.77 
 
Table 3-2: DSC thermostability data.  DspB, HexNW, and buffer samples were gradually 
heated to measure heat capacity.  TG1 and TG2 represent the temperatures at each of 2 thermal 





Table 3-3: Melting point summary.  Melting point was precisely estimated using 2 methods 
(DSC and CD).  
  
DspB HexNW 
Melting point by 
CD  (°C) 
Melting point by 
DSC (°C) 
Melting point by 
CD (°C) 
Melting point by 
DSC (°C) 




 To assess the ability of HexNW to degrade bacterial biofilms, it was 
incubated with 24 hour biofilms of S. epidermidis strain NRS 101.  See Figure 3-
7 for a schematic that illustrates how biofilms were grown and treated.  NRS 101 
was chosen because DspB, a homologue of HexNW, is most effective against 
biofilms of S. epidermidis.  In addition, NRS 101 is a known biofilm producer and 
is also methicillin-resistant, making any antibiofilm activity against the strain 
particularly important due to the growing number of infections caused by 
antibiotic-resistant bacteria.   
In Figure 3-8, the results of an assay comparing the release of amino 
sugars, as measured by the Morgan-Elson assay, between HexNW- and buffer-
treated biofilms is shown.  Since HexNW is predicted to degrade biofilms by 
digesting the polysaccharide portion of the EPS, HexNW treatment should result 
in an increase of soluble amino sugars in the medium surrounding the biofilm.  
Figure 3-8 illustrates a 20% increase in amino sugars released as a result of 




































Figure 3-7: Biofilm treatment schematic.  In (A), inoculation of a well with biofilm-forming 
bacteria is depicted.  After incubation at 37°C without shaking, bacterial cells have multiplied and 
formed a biofilm on the sides and bottom of the well (B).  In (C), the well has been washed and 
buffer has been added.  In (D), the addition of EPS depolymerase is shown and (E) depicts the 
depolymerase-mediated breakdown of the EPS and subsequent release of adherent cells, which 
can be measured by serial dilution and spread plating.  Depolymerase activity on EPS 
polysaccharides can also be measured by performing a sugar-detecting assay such as the Morgan-
Elson assay.  
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Figure 3-8: Morgan-Elson assay.  The number of amino sugars released from S. epidermidis 
biofilms was estimated following HexNW or buffer treatment.  Sugars were detected 


























Next, the effect of HexNW treatment on the dispersal of bacterial cells 
from the biofilm was estimated by measuring the colony-forming units released 
into the treatment medium.  The results, shown in Figure 3-9, demonstrate that 
HexNW treatment released 165% more viable cells than treatment with buffer.  
Release of biofilm cells into the surrounding medium mirrors biofilm cells’ 
dispersal in nature (see Chapter 1), which is specifically mediated by enzymes 
such as DspB that are produced by the biofilm-forming cells.  Being able to 
measure cell dispersal, therefore, is a worthwhile means of detecting the activity 
of EPS depolymerases. 
Finally, the effect of HexNW treatment on the Minimum Biofilm 
Elimination Concentration (MBEC) of vancomycin on S. epidermidis NRS 101 
biofilms was assessed.  The MBEC is defined as the lowest antimicrobial 
concentration tested which results in complete killing of biofilm cells.  This is 
measured by first treating biofilms with various concentrations of an antimicrobial 
and then assessing biofilm cell viability by the addition of growth media.  The 
MBEC is then the lowest antimicrobial concentration that results in no visible 
growth following overnight incubation of treated biofilms in media.  The 
Minimum Inhibitory Concentration (MIC), on the other hand, is the lowest 
concentration of an antibiotic required to prevent planktonic (rather than biofilm) 
cell growth.  Table 3-4 shows the results of testing the effect of HexNW and 
DspB on the MBEC of vancomycin.  It was predicted that the enzymes would 
cause the release of cells from the biofilm and thus reduce the MBEC.  The 
MBEC when vancomycin was supplemented with either 0.05 mg/ml DspB or 
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HexNW was 1,024 µg/ml, whereas the MBEC when only PBS was added was 
2,048 µg/ml, indicating that HexNW and DspB are capable of reducing the 
amount of vancomycin needed to eliminate NRS 101 biofilms by half.  Also 
shown is in Table 3-3 is the MIC of vancomycin for NRS 101, which was found 
to be 4 µg/ml.  Neither DspB nor HexNW treatment had any effect on the MIC of 
vancomycin for NRS 101 (Table 3-4).  The stark contrast between MIC and 
MBEC in the case of vancomycin treating NRS 101 illustrates the protective 





Figure 3-9: CFU release.  Biofilms (grown for 24 hr) were treated with 0.25 mg/ml HexNW or 
PBS buffer.  After 1 hr incubation at 37°C, cells were enumerated by spread plating.  Work done 




























Figure 3-10: Depolymerase-mediated reduction in MBEC.  Vancomysin of varying 
concentrations and HexNW, DspB, or buffer were added to washed S. epidermidis biofilms.  After 
incubation, washing, addition of sterile media, and overnight incubation, sterilized wells result in 
lack of visual growth.  Addition of HexNW or DspB reduces the necessary concentration of 
vancomycin for biofilm sterilization (MBEC) from 2,048 µg/ml to 1,024 µg/ml.  Work done by 
Patrick Bales. 
 
 DspB HexNW Control 
MIC (µg/ml) 4 4 4 
MBEC (µg/ml) 1,024 1,024 2,048 
 
Table 3-4: MBEC and MIC values.  The MBEC values of vancomycin when DspB, HexNW, or 
buffer were added to S. epidermidis biofilms were measured.  Also measured were MIC values.  





 HexNW has been shown to be a thermostable enzyme that has potential as 
a therapeutic against S. epidermidis biofilms.  Because it is active against a 
synthetic N-acetylglucosamine substrate, homologous to DspB (a known β-1,6-N-
acetylglucosaminidase), and not active when used to treat a trimeric chitin 
substrate (which contains N-acetylglucosamine residues linked in β-1,4 linkages), 
it is likely that HexNW is a β-1,6-N-acetylglucosaminidase similar to DspB.  
When used with 4-nitrophenyl N-acetyl-D-glucosaminide as a substrate, HexNW 
was shown to be about half as active as DspB.  It is notable, however, that when 
comparing the MBEC-reducing effects of DspB and HexNW, they perform 
equally well.  Therefore, while HexNW may have less activity than DspB, this 
disparity does not seem to have an effect when HexNW is being used to treat 
actual biofilms. 
 By measuring the activity of HexNW at various pH values, it was 
determined that it is active at physiological pH.  When the resistance of HexNW 
to high-temperatures was tested by incubating at different temperatures and then 
testing activity with 4-nitrophenyl N-acetyl-D-glucosaminide, it was found to be 
highly thermostable.  This was then confirmed by CD and DSC analysis.  
Thermostability is a desirable trait in a therapeutic because it directly correlates 
with shelf life (Anderson and Scott 1991).  One can imagine that a product that is 
capable of long-term storage at room temperature would be much more valuable 
than one that requires constant refrigeration.  In addition, the ability of an 
antimicrobial to function at human body temperature (37°C) is essential.  As 
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shown in Figure 3-6, DspB has a melting temperature (temperature at which 
point about 50% of DspB molecules are unfolded) of about 44°C and begins 
activity loss at about 37°C.  HexNW, on the other hand, has a melting point of 
between 58 and 60°C and is fully active at 37°C.  Future experiments may focus 
on the long-term thermostability of HexNW by assessing activity after extended 
incubation at various temperatures. 
 HexNW has proven to be a promising biofilm depolymerase based on the 
results of multiple experiments.  The increased number of amino sugars in the 
biofilm treatment medium indicates that HexNW treatment is acting to break up 
the polysaccharide portion of the biofilm EPS (Izano et al. 2008).  In addition, 
HexNW treatment resulted in the release of colony-forming units from the 
biofilm.  Finally, HexNW increased the effectiveness of vancomycin treatment of 
S. epidermidis biofilms by lowering the minimum biofilm elimination 
concentration (MBEC) by half.  This experiment is particularly noteworthy 
because these types of therapeutics—those that don’t actually kill bacterial cells 
but simply disperse the biofilm matrix—will likely be used in combination with 
other treatments (such as antibiotics) when applied in clinical situations (Rogers 
et al. 2010).  As HexNW causes the release of cells from the biofilm, the 
accessibility of the bacteria to vancomycin increased and thus lowered the 
concentration of vancomycin required for full sterilization of the peg biofilms.  In 
the future, the ability of HexNW to disrupt biofilms will be further questioned.  
Biofilm flow cells can be used in conjunction with live-dead staining to visualize 
the effect of HexNW on biofilm structure with a confocal microscope.  Catheter 
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models or animal models of infection are other possible experiments.  In addition, 
it will be useful to test HexNW on other strains of S. epidermidis than NRS 101.  
Since DspB has been shown to prevent biofilm formation in S. aureus (Izano et al. 
2008), similar experiments can be done for HexNW.  HexNW might also be used 
to treat E. coli biofilms since E. coli is known to have an appreciable amount of 
N-acetylglucosamine in its EPS (Wang et al. 2004; Bales et al 2013). 
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Other Putative EPS Depolymerases 
 
This chapter contains unpublished preliminary data I collected and partial 
characterization of several enzymes not discussed elsewhere in this thesis. It is 
anticipated that full characterization for some of these enzymes will be continued 
in the laboratory by future graduate students. 
Identification of depolymerases was done by Daniel Nelson and Patrick 
Bales.  Initial characterization of depolymerases was done by Emilija Renke, 
Sarah May, and Patrick Bales.  Additional characterization of all alginate lyases, 
including purification and enzyme activity analysis, was done by Steve Swift.  
Characterization of Tsp1 and other depolymerases was done by Patrick Bales.  
The crystal structure of Tsp1 was determined by Chen Chen, Julia Greenfield, and 
Osnat Herzberg. 
 
Selection of depolymerases 
Efforts to discover biofilm-dispersing agents were focused on enzymes 
that are capable of degrading the polysaccharide portion of the biofilm EPS 
matrix (EPS depolymerases) due to our lab’s experience working with 
antibacterial enzymes, their proven ability to inhibit biofilm formation, and their 
capacity to degrade already-formed, mature biofilms.  The wide structural 
diversity among biofilm organisms’ EPS along with the occurrence of multi-
species biofilms necessitates investigation of methods to treat biofilms based on a 
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broad range of polysaccharase activities.  A summary of EPS depolymerases 
synthesized, expressed, purified, and initially characterized is given in Table 4-1. 
Depolymerase candidates were selected based on thorough literature and 
bioinformatics searches for enzymes that degrade particular polysaccharides 
known to be a main constituent of bacterial biofilms of certain relevant pathogens.  
Alginate, for example, is known to be a significant constituent of P. aeruginosa 






Table 4-1: Summary of synthesized depolymerases.  Fifteen putative EPS depolymerases were 
identified, synthesized, and expressed.  Attempts were made to purify the depolymerases (most 




structural stability.  It is associated highly with the “mucoid” phenotype, which is 
usually the phenotype of P. aeruginosa causing pneumonia in the lungs of cystic 
fibrosis patients.  Toward this end, we searched for and discovered several 
potential alginate lyases (LyaseU, LyaseSD, AlgMsp, LyasePA, and LyaseSM) in 
GenBank and other databases.  All genes were codon-optimized for expression in 
E. coli, chemically synthesized, and cloned into the pBAD24 arabinose-inducible 
expression system.  For the lyases, N-terminal 6-His tags engineered into the gene 
construct for purification caused misfolding and/or the inability to purify the 
recombinant enzyme.  However, when the His tags were moved to the C-
terminus, we were able to purify four of the five enzymes.  Lyase SD continues to 
produce inclusion bodies whether it possesses a tag or not.  Of the four soluble, 
purified alginate lyases, we focused our characterization studies on AlgMsp 
because it has not been previously characterized and it was expressed with the 
highest yields.  Dr. Steve Swift, a postdoctoral associate in our laboratory, took 
over the project during the expression and purification stages.  He has shown that 
AlgMsp is highly active against purified alginate and the full characterization of 
this enzyme has been submitted for publication (see Appendix C).   
Biofilms of K. pneumoniae, despite a high incidence of antibiotic 
resistance (Anderl et al. 2000; Boucher et al. 2009), have not been well studied 
and represent a medically important target for development of anti-biofilm 
enzymes.  Literature searches suggested a role for glucuronic acid in K. 
pneumoniae biofilms (Bessler et al. 1973; Niemann et al. 1977), so 
glucuronidases were considered as possible depolymerases of K. pneumoniae 
100 
 
biofilms.  GlucEQ, GlucNH, and GlucFO listed and described in Table 4-1, were 
synthesized due to putative glucuronidase activity.  Although characterization is 
still preliminary, all three glucuronidases are extremely soluble and can be 
purified in large quantities. 
Similar to K. pneumoniae, Acinetobacter baumanni is also not well 
studied despite its high clinical relevance.  Literature searches suggested a role of 
β-1,4-N-acetylglucosamine in the EPS of A. baumanni (Fregolino et al. 2011; 
Vötsch and Templin 2000).  NagZ, which is produced by A. baumannii and is a 
putative N-acetylglucosaminidase, was therefore synthesized.  This protein is 
related to a protein of the same name which is found in E. coli and is best known 
for its role in the induction of E. coli β-lactamase activity (Asgarali et al. 2009). 
Tailspike proteins of bacteriophages were also considered as possible EPS 
depolymerases because of their recognized role in degrading bacterial EPS so as 
to allow access of the phage to the host cell surface (Ghalambor et al. 1971; 
Müller et al. 2008).  Sf6 is a well-described endorhamnosidase produced by the 
Sf6 phage, which is a P22-like phage of Shigella flexneri (Müller et al. 2008), 
although its role in degradation of biofilms has not been studied in the literature.  
Tsp1 is one of four putative tail spikes of CBA120, a myophage of E. coli 
O157:H7 (Chen et al. 2014).  It is SDS- and protease-resistant, thermostable, and 
exhibits a trimeric, β-sheet-heavy structure that is typical of phage tailspike 
proteins.  While we were evaluating Tsp1 and the other putative depolymerases, 
we were approached by Dr. Osnat Herzberg who was interested in crystallizing 
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Tsp1.  This collaboration yielded two publications on the structural details on this 
enzyme (see Appendix 1 and 2). 
Dispersin B (DspB), a well-studied β-1,6-N-acetylglucosaminidase that 
degrades S. epidermidis biofilms, was synthesized as a control depolymerase with 
a known activity.  In addition, two DspB homologs, NexNW and DspAA, were 
also synthesized. DspAA was not soluble under any expression conditions.  In 
contrast, DspB and HexNW were abundantly soluble and have been described in 
detail in Chapter 3.  By investigating enzymes that degrade 1,6-linked N-
acetylglucosamine, new methods of treating infections caused by bacteria that 
produce this polysaccharide (including S. epidermidis, S. aureus, and E. coli) will 
be uncovered (Wang et al. 2004; Bales et al. 2013). 
Finally, Chapter 2 details an investigation into the structure of the high 
molecular weight polysaccharide portion of the EPS of several pathogens (K. 
pneumoniae, A. baumanni, S. epidermidis, E. coli O157:H7, and P. aeruginosa).  
A salient finding of that study was the high prevalence of mannose detected.  The 
possible preponderance of mannose residues in the EPS of multiple pathogens 
makes mannosidases attractive possibilities as anti-biofilm agents.  For this 
reason, Bdm, a putative mannosidase produced by Xanthomonas campestris pv. 
campetris, was synthesized as a putative depolymerase that may have activity 






Preliminary anti-biofilm experiments 
Preliminary experiments were aimed at demonstrating the potential of 
these enzymes as biofilm-targeting therapeutics.  Briefly, wells of 96-well plates 
were seeded with 1:100 diluted overnight solutions (diluted in T-soy broth) of the 
listed pathogens and EPS depolymerases (0.1 mg/ml final concentration) in a final 
volume of 200 µl.  Plates were incubated at 37°C without shaking to allow 
formation of static biofilms. The wells were then aspirated, washed twice with 
200 µL water, and the biofilm biomass was stained with 0.1% crystal violet for 10 
minutes.  Following dye incubation, the dye was aspirated and the wells washed 
twice with water.  SDS detergent was added (1%) and allowed to sit at room 
temperature for 10 minutes, after which the solution in each well was transferred 
to fresh plates and the OD at 600 nm was read using a Molecular Devices 
SpectraMax M5 spectrophotometer to quantify formation of biofilms in enzyme 
treated vs. PBS control wells.  Depolymerase effectiveness was estimated by 
subtracting the average OD of PBS-treated wells by that of depolymerase treated 
wells, dividing by the OD of PBS-treated wells, multiplying by 100, and then 
subtracting the resulting percentage value from 100. 
According to Figure 4-1, synthesized depolymerases exhibit activity on a 
wide-range of pathogenic bacteria.  Strains that were less affected by 
depolymerase action were P. aeruginosa strains 700888 and 27853.  This may be 
due to the fact that these strains formed biofilms that were less thick than the 
others and thus exhibit decreased sensitivity to this assay.  Interestingly, all 
depolymerases appeared to be active against the same bacterial strains, perhaps 
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owing to the exceptional heterogeneity of bacterial biofilm structure. Future 
members of the Nelson lab will have the opportunity to investigate the enzymatic 






Figure 4-1: Depolymerase–mediated prevention of biofilm formation.  Biofilms of strains 
BAA-2146, 51505, 700603 (K. pneumoniae), 700829, 700888, 10145, 27853, (P. aeruginosa), 
and NRS 101 (S. epidermidis), were grown in the presence of the indicated depolymerases.  Work 





Discussion and Future Directions 
 
A S. epidermidis biofilm-degrading enzyme, HexNW, has been described.  
It exhibits anti-biofilm activity in a way that is very applicable to possible future 
therapeutic applications (synergy with vancomycin reducing its MBEC by one-
half).  For a protein originating from a mesophilic bacterium, it is very 
thermostable with a Tm of about 58-60°C.  Since a large proportion of medical 
implant device-related infections are linked to biofilm-forming strains of S. 
epidermidis (Otto 2012), HexNW has the potential to be clinically useful.  The 
high melting point of HexNW will make it even more useful because it is less 
subject to heat-inactivation when stored in sub-optimal conditions.  
 In addition to HexNW, 14 depolymerases were synthesized and are in 
various stages of analysis.  Taken together, we have synthesized and purified 
enzymes that can potentially degrade the biofilms of many clinically important 
human pathogens, including S. epidermidis, E. coli strain 0157:H7, Pseudomonas 
aeruginosa, Klebsiella pneumonia, and Acinetobacter baumanii.  Previous 
literature and also our findings regarding the EPS exopolysaccharide structure of 
these pathogens indicate that the structure of bacterial biofilms is variable and 
complex.  For this reason, it is likely that in order to effectively disperse the 
biofilms of multiple pathogens, or even a single species, a cocktail of multiple 
enzymes will be needed so as to degrade all of the important structural 




 Future experiments regarding the structural analysis of biofilm 
exopolysaccharides may include utilizing lectin staining to rapidly screen 
bacterial biofilms for certain components (Angeloni et al. 2005).  In addition, 
nuclear magnetic resonance (NMR) may be used to validate data obtained by our 
lab with the help of the Complex Carbohydrate Research Center (Athens, GA).  
Since we have purified several putative biofilm EPS depolymerases (see Table 4-
1) besides HexNW, which has already been investigated in detail, there is a great 
deal of additional investigation left to be done.   
Regarding HexNW, future experiments may focus on the long-term 
thermostability of HexNW by assessing activity after extended incubation at 
various temperatures.  In addition, the regions of HexNW that are responsible for 
catalytic activity and thermostability may be investigated.  Also, the ability of 
HexNW to disrupt biofilms can be questioned further.  Biofilm flow cells can be 
used in conjunction with live-dead staining to visualize the effect of HexNW on 
biofilm structure with a confocal microscope.  Catheter models or animal models 
of infection represent additional lines of investigation.  In addition, it will be 
useful to test HexNW on other strains of S. epidermidis besides NRS 101.  Since 
DspB has been shown to prevent biofilm formation in S. aureus, similar 
experiments can be done for HexNW (Izano et al. 2008).  HexNW might also be 
used to treat E. coli biofilms since E. coli is known to have an appreciable amount 




CONCLUDING REMARKS  
 
 Ample evidence has been provided for the urgent need to develop new 
ways of treating biofilm-related infections.  Due to the large contribution of the 
polysaccharide portion of the EPS to the resilience and adherence properties of 
biofilms, increasing our understanding of the structure of these 
exopolysaccharides and also investing in the discovery of methods to degrade 
them are worthwhile goals.  This thesis has detailed the composition of these 
exopolysaccharides in the biofilms of several important human pathogens.  The 
identification and characterization of HexNW, a novel β-1,6-N-
acetylglucosaminidase, has also been described.  It represents a possible means of 
combating the numerous medical device-related infections caused by S. 
epidermidis.  In addition, many other possible EPS depolymerases have been 
purified and may develop into therapeutics for other bacterial species. This thesis 
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For the last two decades, CASP has assessed the state of the art in techniques 
for protein structure prediction and identified areas which required further 
development. CASP would not have been possible without the prediction targets 
provided by the experimental structural biology community. In the latest 
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experiment, CASP10, more than 100 structures were suggested as prediction 
targets, some of which appeared to be extraordinarily difficult for modeling. In 
this article, authors of some of the most challenging targets discuss which specific 
scientific question motivated the experimental structure determination of the 
target protein, which structural features were especially interesting from a 
structural or functional perspective, and to what extent these features were 
correctly reproduced in the predictions submitted to CASP10. Specifically, the 
following targets will be presented: the acid-gated urea channel, a difficult to 
predict transmembrane protein from the important human pathogen Helicobacter 
pylori; the structure of human interleukin (IL)-34, a recently discovered helical 
cytokine; the structure of a functionally uncharacterized enzyme OrfY from 
Thermoproteus tenax formed by a gene duplication and a novel fold; an ORFan 
domain of mimivirus sulfhydryl oxidase R596; the fiber protein gene product 17 
from bacteriophage T7; the bacteriophage CBA-120 tailspike protein; a virus coat 
protein from metagenomic samples of the marine environment; and finally, an 
unprecedented class of structure prediction targets based on engineered disulfide-






Crystal Structure of ORF210 from E. coli O157:H7 Phage 
CBA120 (TSP1), a Putative Tailspike Protein 
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Bacteriophage tailspike proteins act as primary receptors, often possessing 
endoglycosidase activity toward bacterial lipopolysaccharides or other 
exopolysaccharides, which enable phage absorption and subsequent DNA 
injection into the host. Phage CBA120, a contractile long-tailed Viunalikevirus 
phage infects the virulent Escherichia coli O157:H7. This phage encodes four 
putative tailspike proteins exhibiting little amino acid sequence identity, whose 
biological roles and substrate specificities are unknown. Here we focus on the 
first tailspike, TSP1, encoded by the orf210 gene. We have discovered that TSP1 
is resistant to protease degradation, exhibits high thermal stability, but does not 
cleave the O157 antigen. An immune- dot blot has shown that TSP1 binds 
strongly to non-O157:H7 E. coli cells and more weakly to K. pneumoniae cells, 
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but exhibits little binding to E. coli O157:H7 strains. To facilitate structure-
function studies, we have determined the crystal structure of TSP1 to a resolution 
limit of 1.8 A. Similar to other tailspikes proteins, TSP1 assembles into elongated 
homotrimers. The receptor binding region of each subunit adopts a right-handed 
parallel b helix, reminiscent yet not identical to several known tailspike structures. 
The structure of the N-terminal domain that binds to the virion particle has not 
been seen previously. Potential endoglycosidase catalytic sites at the three subunit 
interfaces contain two adjacent glutamic acids, unlike any catalytic machinery 
observed in other tailspikes. To identify potential sugar binding sites, the crystal 
structures of TSP1 in complexes with glucose, a-maltose, or a-lactose were 
determined. These structures revealed that each sugar binds in a different location 
and none of the environments appears consistent with an endoglycosidase 







Characterization of AlgMsp, an Alginate Lyase 
from Microbulbifer sp. 6532A 
 
This appendix contains the abstract for the following co-authored manuscript that 
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Alginate is a polysaccharide consisting of mannuronic acid and guluronic 
acid residues. It is produced by certain seaweeds and bacteria. Seaweed alginate is 
used in food and industrial chemical processes. Bacterial alginate is characteristic 
to pathogenic Pseudomonas aeruginosa. Alginate lyases cleave this 
polysaccharide into short oligo-uronates, and have potential applications in 
industry and medicine. An alginate lyase gene, algMsp, from Microbulbifer sp. 
6532A, was synthesized as an E.coli codon-optimized clone. The resulting 
protein, AlgMsp, was expressed and purified from E. coli, and then the 
recombinant 37 kDa protein was characterized. The alginate lyase displayed 
highest activity at pH 8 and 0.2 M NaCl. Activity of the alginate lyase was 
greatest at 50°C, but was not stable over time at 50°C. The alginate lyase was still 
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highly active at 25°C, and had little or no loss of activity after 24 hours at 
25°C.  AlgMsp did not require divalent cations for activity. Comparing activity of 
the lyase against polymannuronic acid and polyguluronic acid substrates showed 
higher specific activity with polymannuronic acid, but greater affinity to 
polyguluronic acid. Prolonged AlgMsp-mediated degradation of alginate 






Ander JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in 
Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. 
Antimicrobial agents chemother. 2000; 44(7):1818-1824. 
Anderson G, Scott M. Determination of product shelf life and activation energy 
for five drugs of abuse. Clinical chemistry. 1991; 37:398–402. 
Anderson S.  Characterization of bacterial biofilms for wastewater treatment. 
Stockholm: Royal Institute of Technology, Thesis (2009). 
Angeloni S, Ridet JL, Kusy N, Gao H, Crevoisier F, Guinchard S, Kochhar S, 
Sigrist H, Sprenger N. Glycoprofiling with micro-arrays of glycoconjugates and 
lectins. Glycobiology. 2005; 15:31–41. 
Asgarali A, Stubbs K, Oliver A, Vocadlo DJ, Mark BL. Inactivation of the 
glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in 
Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy. 2009; 
53(6):2274–82.  
Bales PM, Renke EM, May SL, Shen Y, Nelson DC. Purification and 
characterization of biofilm-associated EPS exopolysaccharides from ESKAPE 
organisms and other pathogens. PloS One. 2013; 8(6):e67950.  
Banerjee I, Pangule RC, Kane RS. Antifouling coatings: recent developments in 
the design of surfaces that prevent fouling by proteins, bacteria, and marine 
organisms. Advanced materials. 2011; 23(6):690–718.  
Bartell PF, Orr TE. Origin of polysaccharide depolymerase associated with 
bacteriophage infection. Journal of virology. 1969; 3(3):290–6.  
Bessler W, Freund-Molbert E, Knufermann H, Rudolph C, Thurow H, Stirm S. A 
bacteriophage-induced depolymerase active on Klebsiella K11 capsular 
polysaccharide. Virology. 1973; 56(1):134–151. 
Biscola FT, Abe CM, Guth BEC. Determination of adhesin gene sequences in, 
and biofilm formation by, O157 and non-O157 Shiga toxin-producing 
Escherichia coli strains isolated from different sources. Applied and 




Böckelmann U, Janke A, Kuhn R, Neu TR, Wecke J, Lawrence JR, Szewzyk U. 
Bacterial extracellular DNA forming a defined network-like structure. FEMS 
microbiology letters. 2006; 262(1):31–8.  
Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of 
novel antibiotic lock solutions in a model against isolates of catheter-related 
bloodstream infections. The Annals of pharmacotherapy. 2009; 43:210–219. 
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, 
Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the 
Infectious Diseases Society of America. Clinical infectious diseases  : an official 
publication of the Infectious Diseases Society of America. 2009; 48:1–12. 
Byrd MS, Sadovskaya I, Vinogradov E, Lu H, Sprinkle AB, Richardson SH, Ma 
L, Ralston B, Parsek MR, Anderson EM, et al. Genetic and biochemical analyses 
of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles 
for polysaccharide synthesis enzymes in Psl and LPS production. Molecular 
microbiology. 2009; 73:622–638. 
Calhoun JH, Murray CK, Manring MM. Multidrug-resistant organisms in military 
wounds from Iraq and Afghanistan. Clinical orthopaedics and related research. 
2008; 466(6):1356–62.  
Campoccia D, Montanaro L, Arciola CR. A review of the clinical implications of 
anti-infective biomaterials and infection-resistant surfaces. Biomaterials. 2013; 
34(33):8018–29.  
Carlson G, Dragoo JL, Samimi B, Bruckner D a, Bernard GW, Hedrick M, 
Benhaim P. Bacteriostatic properties of biomatrices against common orthopaedic 
pathogens. Biochemical and biophysical research communications. 2004; 
321(2):472–8.  
Casjens SR, Thuman-Commike PA. Evolution of mosaically related tailed 
bacteriophage genomes seen through the lens of phage P22 virion assembly. 
Virology. 2011; 411:393–415. 
Chaignon P, Sadovskaya I, Ragunah C, Ramasubbu N, Kaplan JB, Jabbouri S. 
Susceptibility of staphylococcal biofilms to enzymatic treatments depends on 
their chemical composition. Applied microbiology and biotechnology. 2007; 
75:125–132. 
Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. 
Toxicology letters. 2008; 176(1):1–12.  
Choi AHK, Slamti L, Avci FY, Pier GB, Maira-Litrán T. The pgaABCD locus of 
Acinetobacter baumannii encodes the production of poly-beta-1-6-N-
acetylglucosamine, which is critical for biofilm formation. Journal of 
bacteriology. 2009; 191(19):5953–63.  
117 
 
Ciucanu I, Kerek F. A simple and rapid method for the permethylation of 
carbohydrates. Carbohydrate research. 1984; 131:209–217. 
Comte S, Guibaud G, Baudu M. Effect of extraction method on EPS from 
activated sludge: An HPSEC investigation. Journal of hazardous materials. 2007; 
140:129–137. 
Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F. The intercellular 
adhesion (ica) locus is present in Staphylococcus aureus and is required for 
biofilm formation. Infection and immunity. 1999; 67:5427–5433. 
Crawford RW, Gibson DL, Kay WW, Gunn JS. Identification of a bile-induced 
exopolysaccharide required for Salmonella biofilm formation on gallstone 
surfaces. Infection and immunity. 2008; 76:5341–5349. 
Cristensen GD, Barker LP, Mawhinney TP, Baddour LM, Simpson WA. 
Identification of an antigenic marker of slime production for Staphylococcus 
epidermidis. Infection and immunity. 1990; 58:2906–2911. 
Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford B a, Crowley JR, Henderson 
JP, Janetka JW, Hultgren SJ. Treatment and prevention of urinary tract infection 
with orally active FimH inhibitors. Science translational medicine. 2011; 
3(109):109-115.  
Danese PN, Pratt LA, Kolter R. Exopolysaccharide production is required for 
development of Escherichia coli K-12 biofilm architecture. Journal of 
bacteriology. 2000; 182:3593–3596. 
Darouiche RO, Mansouri MD, Gawande P V, Madhyastha S. Antimicrobial and 
antibiofilm efficacy of triclosan and DispersinB combination. The Journal of 
antimicrobial chemotherapy. 2009; 64(1):88–93. 
Davies DG. The involvement of cell-to-cell signals in the development of a 
bacterial biofilm. Science. 1998; 280(5361):295–298.  
Desrousseaux C, Sautou V, Descamps S, Traoré O. Modification of the surfaces 
of medical devices to prevent microbial adhesion and biofilm formation. The 
Journal of hospital infection. 2013; 85(2):87–93.  
Dibdin GH, Assinder SJ, Nichols WW, Lambert P. Mathematical model of beta-
lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing 
simultaneous inactivation by released beta-lactamases. The Journal of 
antimicrobial chemotherapy. 1996; 38(5):757–69.  
Donelli G, Francolini I, Romoli D, Guaglianone E, Piozzi a, Ragunath C, Kaplan 
JB. Synergistic activity of dispersin B and cefamandole nafate in inhibition of 
staphylococcal biofilm growth on polyurethanes. Antimicrobial agents and 
chemotherapy. 2007; 51(8):2733–40.  
118 
 
Donlan RM. Preventing biofilms of clinically relevant organisms using 
bacteriophage. Trends in microbiology. 2009; 17(2):66–72.  
DuBois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method 
for determination of sugars and related substances. Analytical chemistry. 1956; 
28:350–356.  
Elsässer-Beile U, Friebolin H, Stirm S.  Primary structure of Klebsiella serotype 6 
capsular polyssacharide. Carbohydr research. 1978; 65: 245–249. 
Fallas JA, Hartgerink JD. Computational design of self-assembling register-
specific collagen heterotrimers. Nature communications. 2012; 3:1087. 
Fazekas E, Kandra L, Gyemant G. Model for β-1,6-N-acetylglucosamine 
oligomer hydrolysis catalyzed by dispersinB, a biofilm degrading enzyme. 
Carbohydrate research. 2012; 363:7-13. 
Flemming H-C, Wingender J. The biofilm matrix. Nature reviews microbiology. 
2010; 8:623–633. 
Flemming, H-C JW. Relevance of microbial extracellular polymeric substances 
(EPSs) - Part I: Structural and ecological aspects. Water science and technology. 
1999; 43:1–8. 
Fregolino E, Gargiulo V, Lanzetta R, Parrilli M, Holst O, Castro C De. 
Identification and structural determination of the capsular polysaccharides from 
two Acinetobacter baumannii clinical isolates, MG1 and SMAL. Carbohydrate 
research. 2011; 346(7):973–7. 
Friedman L, Kolter R. Genes involved in matrix formation in Pseudomonas 
aeruginosa PA14 biofilms. Molecular microbiology. 2004; 51:675–690. 
Friedman L, Kolter R. Two genetic loci produce distinct carbohydrate-rich 
structural components of the Pseudomonas aeruginosa biofilm matrix. Journal of 
bacteriology. 2004; 186:4457–4465. 
Gerke C, Kraft A, Schweitzer O, Chem JB, Su R. Characterization of the N-
acetylglucosaminyltransferase activity involved in the biosynthesis of the 
Staphylococcus epidermidis polysaccharide intercellular adhesin. Journal 
biological chemistry. 1998; 273(29):18586-93. 
Ghalambor ALI, Duckworth DH, Edward C. Catalytic capsular and molecular 
polysaccharide properties of a phage induced depolyrnerase. Journal biological 
chemistry. 1971; 246:5607-5616. 




Guiton PS, Hung CS, Kline K a, Roth R, Kau AL, Hayes E, Heuser J, Dodson 
KW, Caparon MG, Hultgren SJ. Contribution of autolysin and sortase a during 
Enterococcus faecalis DNA-dependent biofilm development. Infection and 
immunity. 2009; 77(9):3626–38.  
Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural 
environment to infectious diseases. Nature reviews microbiology. 2004; 2:95–
108.  
Harjai K, Kumar R, Singh S. Garlic blocks quorum sensing and attenuates the 
virulence of Pseudomonas aeruginosa. FEMS immunology and medical 
microbiology. 2010; 58(2):161–8.  
Hughes KA, Sutherland IW, Jones M V. Biofilm susceptibility to bacteriophage 
attack: the role of phage-borne polysaccharide depolymerase. Microbiology. 
1998; 144:3039–3047. 
Izano E a, Amarante M a, Kher WB, Kaplan JB. Differential roles of poly-N-
acetylglucosamine surface polysaccharide and extracellular DNA in 
Staphylococcus aureus and Staphylococcus epidermidis biofilms. Applied and 
environmental microbiology. 2008; 74(2):470–6.  
Junkins AD, Doyle MP. Demonstration of exopolysaccharide production by 
enterohemorrhagic Escherichia coli. Current microbiology. 1992; 25:9–17. 
Kaku H, Van Damme EJ, Peumans WJ, Goldstein IJ. Carbohydrate-binding 
specificity of the daffodil (Narcissus pseudonarcissus) and amaryllis 
(Hippeastrum hybr.) bulb lectins. Archives of biochemistry and biophysics. 1990 
June;279(2):298–304.  
Kalishwaralal K, BarathManiKanth S, Pandian SRK, Deepak V, Gurunathan S. 
Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa 
and Staphylococcus epidermidis. Colloids and surfaces. B, biointerfaces. 2010; 
79(2):340–4.  
Kaplan JB, Ragunath C, Ramasubbu N, Fine DH. Detachment of Actinobacillus 
actinomycetemcomitans biofilm cells by an endogenous beta-hexosaminidase 
activity. Journal of bacteriology. 2003; 185:4693–4698. 
Kaplan JB, Ragunath C, Velliyagounder K, Fine DH, Ramasubbu N. Enzymatic 
detachment of Staphylococcus epidermidis biofilms. Antimicrobial agents and 
chemotherapy. 2004; 48:2633–2636. 
Kaplan JB, Velliyagounder K, Ragunath C, Rohde H, Mack D, Knobloch JK-M, 
Ramasubbu N. Genes involved in the synthesis and degradation of matrix 
polysaccharide in Actinobacillus actinomycetemcomitans and Actinobacillus 
pleuropneumoniae biofilms. Journal of bacteriology. 2004; 186:8213–8220. 
120 
 
Kaplan N, Rosenberg E, Jann B, Jann K. Structural studies of the capsular 
polysaccharide of Acinetobacter calcoaceticus BD4. European journal of 
biochemistry/FEBS. 1985; 152:453–458. 
Kassa T, Chhibber S. Thermal treatment of the bacteriophage lysate of Klebsiella 
pneumoniae B5055 as a step for the purification of capsular depolymerase 
enzyme. Journal of virological methods. 2012; 179(1):135–41.  
Kharidia R, Liang JF. The activity of a small lytic peptide PTP-7 on 
Staphylococcus aureus biofilms. Journal of microbiology. 2011; 49(4):663–8.  
Kives J, Orgaz B, SanJos C. Polysaccharide differences between planktonic and 
biofilm-associated EPS from Pseudomonas fluorescens B52. Colloids and 
surfaces B: biointerfaces. 2006; 52:123–127. 
Kolodkin-Gal I, Cao S, Chai L, Böttcher T, Kolter R, Clardy J, Losick R. A self-
produced trigger for biofilm disassembly that targets exopolysaccharide. Cell. 
2012; 149(3):684–92.  
Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R. D-amino acids 
trigger biofilm disassembly. Science. 2010; 328(5978):627–9.  
Körstgens V, Flemming HC, Wingender J, Borchard W. Influence of calcium ions 
on the mechanical properties of a model biofilm of mucoid Pseudomonas 
aeruginosa. Water science and technology. 2001; 43:49–57. 
Kostakioti, M.K., Hadjifrangiskou, M. H. Bacterial biofilms: development, 
dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold 
spring harb perspect med. 2013; 3(4):a010306. 
Lawrence JR, Korber DR, Hoyle BD, Costerton JW, Caldwell DE. Optical 
sectioning of microbial biofilms. Journal of bacteriology. 1991; 173(20):6558–67.  
Lawrence JR, Swerhone GDW, Kuhlicke U, Neu TR. In situ evidence for 
microdomains in the polymer matrix of bacterial microcolonies. Canadian journal 
of microbiology. 2007; 3(3):450–8.  
Lery LM, Frangeul L, Tomas A, Passet V, Almeida AS, Bialek-Davenet S, Barbe 
V, Bengoechea J a, Sansonetti P, Brisse S, et al. Comparative analysis of 
Klebsiella pneumoniae genomes identifies a phospholipase D family protein as a 
novel virulence factor. BMC biology. 2014 May 29;12(1):41.  
Lewis K. Riddle of biofilm resistance. Antimicrobial agents and chemotherapy. 
2001; 45:999–1007. 
Liu H, Fang HHP. Extraction of extracellular polymeric substances (EPS) of 
sludges. Journal of biotechnology. 2002; 95:249–256. 
121 
 
Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. 
Proceedings of the National Academy of Sciences of the United States of 
America. 2007; 104(27):11197–202.  
Mack D, Nedelmann M, Krokotsch A, Schwarzkopf A, Heesemann J, Laufs R. 
Characterization of transposon mutants of biofilm-producing Staphylococcus 
epidermidis impaired in the accumulative phase of biofilm production: genetic 
identification of a hexosamine-containing polysaccharide intercellular adhesin. 
Infection and immunity. 1994; 62:3244–3253. 
Mann EE, Wozniak DJ. Pseudomonas biofilm matrix composition and niche 
biology. FEMS microbiology reviews. 2012; 36(4):893-916.  
Manuel SGA, Ragunath C, Sait HBR, Izano EA, Kaplan JB. Role of active-site 
residues of dispersinB, a biofilm-releasing β-hexosaminidase from a periodontal 
pathogen, in substrate hydrolysis. FEBS journal. 2007; 274:5987-5999. 
Marchler-Bauer A et al. CDD: conserved domains and protein three-dimensional 
structure. Nucleic Acids Res. 2013;41(D1):D384-52. 
Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JI, Jensen P, Johnsen 
AH, Givskov M, Ohman DE, Molin S, et al. Mucoid conversion of Pseudomonas 
aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the 
cystic fibrosis lung. Microbiology. 1999; 145:1349–1357. 
Matsukawa M, Greenberg EP. Putative exopolysaccharide synthesis genes 
influence Pseudomonas aeruginosa biofilm development. Journal of bacteriology. 
2004; 186:4449–4456. 
Merkle RK, Poppe I. Methanolysis Solvolysis. Methods in enzymology. 1994; 
230:3–15. 
Molin S, Tolker-Nielsen T. Gene transfer occurs with enhanced efficiency in 
biofilms and induces enhanced stabilisation of the biofilm structure. Current 
opinion in biotechnology. 2003; 14(3):255–261.  
Monds RD, O’Toole G. The developmental model of microbial biofilms: ten 
years of a paradigm up for review. Trends in microbiology. 2009; 17(2):73–87.  
Müller JJ, Barbirz S, Heinle K, Freiberg A, Seckler R, Heinemann U. An 
intersubunit active site between supercoiled parallel beta helices in the trimeric 
tailspike endorhamnosidase of Shigella flexneri Phage Sf6. Structure. 2008; 
16(5):766–75.  
National Institutes of Health. Research on Microbial Biofilms (PA-03-047).  
National Institutes of Health.  2002 
122 
 
Niemann H, Kwiatkowski B, Westphal U, Stirm S. Klebsiella serotype 25 
capsular polysaccharide: primary structure and depolymerization by a 
bacteriophage-borne glycanase. Journal of bacteriology. 1977; 130(1):366–74.  
Njoroge J, Sperandio V. Jamming bacterial communication: new approaches for 
the treatment of infectious diseases. EMBO molecular medicine. 2009; 1(4):201–
10.  
O’Toole G, Kolter R. Flagellar and twitching motility are necessary for 
Pseudomonas aeruginosa biofilm development. Molecular microbiology. 1998; 
30(2):295–304.  
Oliveira R, Marques F, Azeredo J. Purification of polysaccharides from a biofilm 
matrix by selective precipitation of proteins. Biotechnology techniques. 1999; 
13(6):391–393.  
Otto M. Molecular basis of Staphylococcus epidermidis infections. Seminars in 
immunopathology. 2012; 34(2):201–14.  
Otzen D, Nielsen PH. We find them here, we find them there: functional bacterial 
amyloid. Cellular and molecular life sciences. 2008; 65(6):910–27.  
Pan X, Liu J, Zhang D, Chen X, Li L, Song W, Yang J. A comparison of five 
extraction methods for extracellular polymeric substances (EPS) from biofilm by 
using three dimensional excitation-emission matrix (3DEEM) fluorescence 
spectroscopy. Water SA. 2010; 36:111-116. 
Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease 
pathogenesis. Annual review of microbiology. 2003; 57:677–701. 
Peters GF, Schumacher-Perdreau B, Jansen M, Bay M, Pulverer G.  Biology of S. 
epidermidis extracellular slime. Zentrabl bakteriol suppl. 1987; 16:15–32. 
Pier GB, Cohen M, Jennings H. Further purification and characterization of high-
molecular-weight polysaccharide from Pseudomonas aeruginosa. Infection and 
immunity. 1983 December;42(3):936–41. 
Pompilio a, Scocchi M, Pomponio S, Guida F, Di Primio a, Fiscarelli E, Gennaro 
R, Di Bonaventura G. Antibacterial and anti-biofilm effects of cathelicidin 
peptides against pathogens isolated from cystic fibrosis patients. Peptides. 2011; 
32(9):1807–14.  
Provencher SW, Glöckner J. Estimation of globular protein secondary structure 
from circular dichroism. Biochemistry. 19816; 20(1):33–7.  
Puckett SD, Taylor E, Raimondo T, Webster TJ. The relationship between the 




Qin Z, Yang L, Qu D, Molin S, Tolker-Nielsen T. Pseudomonas aeruginosa 
extracellular products inhibit staphylococcal growth, and disrupt established 
biofilms produced by Staphylococcus epidermidis. Microbiology. 2009; 
155:2148–56. 
Rättö M, Mustranta A, Siika-aho M. Strains degrading polysaccharides produced 
by bacteria from paper machines. Applied microbiology and biotechnology. 2001; 
57:182–185. 
Revdiwala S, Rajdev BM, Mulla S. Characterization of bacterial etiologic agents 
of biofilm formation in medical devices in critical care setup. Critical care 
research and practice. 2012; 2012:945805. 
Rogers S, Huigens RW, Cavanagh J, Melander C. Synergistic effects between 
conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. 
Antimicrobial agents and chemotherapy. 201; 54(5):2112–8.  
Ryder C, Byrd M, Wozniak DJ. Role of polysaccharides in Pseudomonas 
aeruginosa biofilm development. Current opinion in microbiology. 2007; 
10(6):644–8.  
Sandal I, Inzana TJ, Molinaro A, Castro C De, Shao JQ, Apicella MA, Cox AD, 
Michael FS, Berg G. Identification, structure, and characterization of an 
exopolysaccharide produced by Histophilus somni during biofilm formation. 
BMC Microbiology. 2011; 11:186 doi: 10.1186/1471-2180-11-186. 
Sauer K, Camper AK. Characterization of phenotypic changes in Pseudomonas 
putida in response to surface-associated growth. Journal bacterial. 2001; 183(22): 
6579-89. 
Secinti KD, Özalp H, Attar A, Sargon MF. Nanoparticle silver ion coatings inhibit 
biofilm formation on titanium implants. Journal of clinical neuroscience. 2011; 
18(3):391–5.  
Seo MJ. Biochemical characterization of the exopolysaccharide purified from 
Laetiporus sulphureus mycelia. Journal of microbiology and biotechnology. 2011; 
21:1287–1293. 
Sepandj F, Ceri H, Gibb A, Read R, Olson M. Minimum inhibitory concentration 
(MIC) versus minimum biofilm eliminating concentration (MBEC) in evaluation 
of antibiotic sensitivity of gram-negative bacilli causing peritonitis. Peritoneal 
dialysis international. 2004; 24(1):65–7.  
Shaw T, Winston M, Rupp CJ, Klapper I, Stoodley P. Commonality of elastic 
relaxation times in biofilms. Physical review letters. 2004; 93(9):098102.  
124 
 
Shemesh M, Tam A, Steinberg D. Expression of biofilm-associated genes of 
Streptococcus mutans in response to glucose and sucrose. Journal of medical 
microbiology. 2007; 56:1528–1535. 
Shibata H, Yagi T. Rate assay of N-acetyl-β-D-hexosaminidase with 4-
nitrophenyl N-acetyl-β-D-glucosaminide as an artificial substrate. Clinica chimica 
acta. 1996; 251:53–64.  
Sreerama N, Woody RW. Estimation of protein secondary structure from circular 
dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods 
with an expanded reference set. Analytical biochemistry. 2000; 287:252–260. 
Stevenson G, Andrianopoulos K, Hobbs M, Reeves PR. Organization of the 
Escherichia coli K-12 gene cluster responsible for production of the extracellular 
polysaccharide colanic acid. Journal of bacteriology. 1996; 178:4885–4893. 
Stewart PS, Franklin MJ. Physiological heterogeneity in biofilms. Nature reviews 
microbiology. 2008; 6(3):199–210.  
Stoodley P, Cargo R, Rupp CJ, Wilson S, Klapper I. Biofilm material properties 
as related to shear-induced deformation and detachment phenomena. Journal of 
industrial microbiology & biotechnology. 2002; 29:361–367. 
Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex 
differentiated communities. Annual review of microbiology. 2002; 56:187–209.  
Strathmann M, Wingender J, Flemming HC. Application of fluorescently labelled 
lectins for the visualization and biochemical characterization of polysaccharides 
in biofilms of Pseudomonas aeruginosa. Journal of microbiological methods. 
2002; 50:237–248. 
Strominger JL, Park JT, Thompson RE, Thompson E. Composition of the cell 
wall of Staphylococcus aureus: its relation to the mechanism of action of 
penicillin. Journal of biological chemistry. 1959; 234:3263–3268. 
Sutherland I. Biofilm exopolysaccharides: a strong and sticky framework. 
Microbiology. 2001; 147:3–9. 
Sutherland IW, Hughes KA, Skillman LC, Tait K. The interaction of phage and 
biofilms. FEMS microbiology letters. 2004; 232:1–6. 
Sutherland IW, Wilkinson JF. Depolymerases for bacterial exopolysaccharides 
obtained from phage-infected bacteria. Journal of general microbiology. 1965; 
39(3):373–83.  
Sutherland IW. Structural studies on colanic acid, the common exopolysaccharide 




Taraszkiewicz A, Fila G, Grinholc M, Nakonieczna J. Innovative strategies to 
overcome biofilm resistance. Biomedical research international. 2013; doi: 
10.1155/2013/150653. 
Thompson JE, Pourhossein M, Waterhouse A, Hudson T, Goldrick M, Derrick JP, 
Roberts IS. The K5 lyase KflA combines a viral tail spike structure with a 
bacterial polysaccharide lyase mechanism. The Journal of biological chemistry. 
2010; 285(31):23963–9.  
Tojo M, Yamashita N, Goldmann DA, Pier GB. Isolation and characterization of 
a capsular polysaccharide adhesin from Staphylococcus epidermidis. The Journal 
of infectious diseases. 1988; 157:713–722. 
Tsuneda S, Aikawa H, Hayashi H, Yuasa A, Hirata A. Extracellular polymeric 
substances responsible for bacterial adhesion onto solid surface. FEMS 
microbiology letters. 2003; 223:287–292. 
von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical 
devices: pathogenesis, management and prophylaxis. Drugs. 2005; 65:179–214. 
Vötsch W, Templin MF. Characterization of a beta-N-acetylglucosaminidase of 
Escherichia coli and elucidation of its role in muropeptide recycling and beta -
lactamase induction. The Journal of biological chemistry. 2000; 275(50):39032–8.  
Walters, MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of 
antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance 
of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob 
agents chemother. 2003; 47(1):317-23. 
Wang X, Iii JFP, Romeo T. The pgaABCD Locus of Escherichia coli promotes 
the synthesis of a polysaccharide adhesin required for biofilm formation. Journal 
bacteriol. 2004; 186(9):2724-34. 
Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA 
required for bacterial biofilm formation. Science. 2002; 295(5559):1487.  
Whitfield C. Biosynthesis and assembly of capsular polysaccharides in 
Escherichia coli. Annual review of biochemistry. 2006 January;75:39–68. 
Whitfield C, Roberts IS. Structure, assembly and regulation of expression of 
capsules in Escherichia coli. Molecular microbiology. 1999; 31:1307–1319. 
Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary 
structure analyses from circular dichroism spectroscopic data. Nucleic acids 
research. 2004; 32:W668–W673. 
Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, 
Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen 
126 
 
concentration in airway Pseudomonas infections of cystic fibrosis patients. 
Journal clinical investigation. 2002; 109(3):317–325. 
Wozniak DJ, Wyckoff TJO, Starkey M, Keyser R, Azadi P, O’Toole G, Parsek 
MR. Alginate is not a significant component of the extracellular polysaccharide 
matrix of PA14 and PAO1 Pseudomonas aeruginosa biofilms. Proceedings of the 
National Academy of Sciences of the United States of America. 2003; 
100(13):7907–12.  
Yadav KK, Mandal AK, Sen IK, Chakraborti S, Islam SS, Chakraborty R. 
Flocculating property of extracellular polymeric substances produced by a 
biofilm-forming bacterium Acinetobacter junii BB1A. Applied biochemistry and 
biotechnology. 2012; 168(6):1621-34. 
Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in 
immunity: more than just microbicidal. Trends in immunology. 2002; 23(6):291–
6.  
York WS, Darvill AG, McNeil M, Stevenson TT, Albersheim P.  Isolation and 
characterization of plant cell walls and cell wall components. Methods 
Enzymol.  1986; 118: 3–4. 
Zogaj X, Nimtz M, Rohde M, Bokranz W, Römling U. The multicellular 
morphotypes of Salmonella typhimurium and Escherichia coli produce cellulose 
as the second component of the extracellular matrix. Molecular microbiology. 
2001; 39(6):1452–63. 
 
